

## **Selective Chlorination of Iminosydnonones for Fast Release of Amide, Urea and Sulfonamide-Containing Drugs**

Minghao Feng,<sup>[a]</sup> Léa Madegard,<sup>[a]</sup> Margaux Riomet,<sup>[a]</sup> Manon Louis,<sup>[a]</sup> Pier Alexandre  
Champagne,<sup>[b]</sup> Grégory Pieters,<sup>[a]</sup> Davide Audisio<sup>[a]</sup> and Frédéric Taran<sup>[a]</sup>

[a] Université Paris Saclay, CEA, INRAE, Département Médicaments et Technologies  
pour la Santé (DMTS), SCBM, 91191 Gif-sur-Yvette, France.

[b] Department of Chemistry and Environmental Science, New Jersey Institute of  
Technology, Newark, New Jersey 07102, United States

E-mail: frederic.taran@cea.fr

# Table of contents

I.	Materials and equipments.....	3
II.	Synthetic Procedure and Analytical Data .....	4
1.	Procedure and analytical data of iminosydnone precursors.....	4
2.	Procedure and analytical data for chlorination of iminosydnones .....	12
3.	Procedure and analytical data for bromination of iminosydnones.....	12
III.	Kinetic data for Iminosydnone/Cyclooctyne cycloaddition .....	25
IV.	Stability of chlorinated iminosydnones.....	36
V.	NMR Spectra.....	30
VI.	DFT calculations.....	59

## I. Materials and equipments

### **Reactants and solvents:**

Unless otherwise noted, all reactions were carried out in oven-dried glassware.

Commercially available chemicals were purchased from ABCR, Acros Organics, Sigma-Aldrich, Alfa Aesar, Combi-Blocks, Carbolution, Fluorochem, and TCI Europe and used as received unless otherwise stated. The following solvents were dried by distillation over the drying agents indicated in parentheses: THF (Sodium), Dichloromethane (CaH<sub>2</sub>). Additional anhydrous solvents were purchased from Acros Organics, SigmaAldrich, Alfa Aesar and stored over molecular sieves under an argon atmosphere.

tBuOCl (**5**) was prepared according to the literature<sup>1</sup>.

### **Purifications:**

*Flash chromatography* were performed on silica gel (Merck Kieselgel 60, grading 40-63 μm) or using automate Combiflash® Rf Teledyne ISCO with pre-packed column RediSep® Rf (grading 35-70 μm).

### **Analysis:**

Reactions were monitored by TLC carried out on silica 0,25 mm (60 F254, Merck) using UV light as visualizing agent. For staining, the TLC plates were dipped into a solution basic aqueous permanganate (1 g KMnO<sub>4</sub>, 6 g K<sub>2</sub>CO<sub>3</sub> and 0.1 g KOH in 100 mL H<sub>2</sub>O) and developed with a heat gun.

*Nuclear Magnetic Resonance (NMR) Spectroscopy:* <sup>1</sup>H NMR (400 MHz), <sup>13</sup>C NMR (100 MHz) were measured on a Bruker Avance 400 MHz spectrometer. Chemical shifts are reported in parts per million (ppm) downfield from residual solvents peaks and coupling constants are reported as Hertz (Hz). Splitting patterns are designated as singlet (s), broad singlet (br. s), doublet (d), triplet (t), quartet (q), quintet (quint), multiplet (m). Splitting patterns that could not be interpreted or easily visualized are designated as multiplet (m).

*Electrospray mass spectra* were obtained using an ESI-Quadripole autopurify, Waters (pump: 2545, mass: ZQ2000) mass Spectrometer.

*LC-MS* spectra were recorded on a Waters Acquity UPLC® equipped PDA eλ Detector and SQ Detector 2, mobile phase A: H<sub>2</sub>O + 0.1% formic acid, mobile phase B: acetonitrile + 0.1% formic acid.

High resolution mass spectroscopy of the final compounds were determined using a Xevo® G2-XS QToF.

*Infrared spectra (IR)* were obtained on a Perkin Elmer UATR TWO FTIR spectrophotometer and are reported as wavelength numbers (cm<sup>-1</sup>).

*Melting points (Mp)* were obtained on a BÜCHI Melting Point B-545 and are reported in °C.

*Absorbances* were measured on a Molecular Device SpectraMax® M5e.

---


<sup>1</sup> M. J. Mintz and C. Walling, *Org. Synth.* **1969**, *49*, 9.

## II. Synthetic Procedure and Analytical Data


### 1. Procedure and analytical data of iminosydnone precursors

The synthesis of iminosydnone **6a**, **6b**, **IS6**, **IS7**, **IS8**, **IS9**, **IS10**, **IS14**, **IS16** and **IS17** were previously described by our group and others.<sup>2</sup>

#### General procedure A : amide coupling of iminosydnone substrates



#### iminosydnone salt involved:




To a solution of iminosydnone salt (1.0 equiv.) in DMF (0.3 M) was added carboxylic acid (1.5 equiv.) followed by HATU (2.0 equiv.). The reaction was stirred at room temperature for 20 min before cooled to -30 °C. DIPEA (4.0 equiv.) was added and the mixture was warmed to room temperature and stirred during 6 hours. A saturated NH<sub>4</sub>Cl aqueous solution (15 mL) was added and the mixture was extracted with EtOAc (3 x 20 mL). Organic layers were combined, dried over MgSO<sub>4</sub> and filtered. Solvents were evaporated under vacuum and the crude was purified by flash chromatography (heptane/ethyl acetate) on silica gel to give the desired product.

<sup>2</sup> For compounds **6a**, **IS7** and **IS16**, see: M. Riomet, E. Decuypere, K. Porte, S. Bernard, L. Plougastel, S. Kolodych, D. Audisio, F. Taran, *Chem. Eur. J.* **2018**, *24*, 8535–8541; for compounds **6b** and **IS17** see: Z. Shao, W. Liu, H. Tao, F. Liu, R. Zeng, P. A. Champagne, Y. Cao, K. N. Houk, Y. Liang, *Chem. Commun.* **2018**, *54*, 14089–14092; for compounds **IS6**, **IS9**, **IS10** and **IS14** see: M. Riomet, K. Porte, L. Madegard, P. Thuéry, D. Audisio, F. Taran, *Org. Lett.* **2020**, *22*, 2403–2408; for compound **IS8**, see: S. Bernard, D. Audisio, M. Riomet, S. Bregant, A. Sallustrau, L. Plougastel, E. Decuypere, S. Gabillet, R. Arun Kumar, J. Elyian, M. Nguyet Trinh, O. Koniev, A. Wagner, S. Kolodych and Frédéric Taran, *Angew. Chem. Int. Ed.* **2017**, *56*, 15612–15616.

**IS1**

(S)-4-(((9H-fluoren-9-yl)methoxy)carbonyl)amino-5-(tert-butoxy)-5-oxopentanoyl(3-(4-(propionyloxy)phenyl)-1,2,3-oxadiazol-3-ium-5-yl)amide



$C_{35}H_{36}N_4O_8$   
**MW:** 640 g.mol<sup>-1</sup>  
**Yield:** 63%  
 Yellow foam

The product was obtained following the General Procedure A using iminosydnone **6b** (89.2 mg, 0.33 mmol, 1.0 equiv.), Fmoc-Glu-OtBu (210 mg, 0.50 mmol, 1.5 equiv.), HATU (213 mg, 0.66 mmol, 2.0 equiv.) and DIPEA (170 mg, 1.33 mmol, 4.0 equiv.) to give the desired product in 63% yield (132 mg, 0.21 mmol).

<sup>1</sup>H NMR (400 MHz, MeOD) δ 8.68 (s, 1H), 8.28 – 8.20 (m, 2H), 8.04 (d, *J* = 8.8 Hz, 2H), 7.73 (d, *J* = 7.4 Hz, 2H), 7.63 (dd, *J* = 6.9, 5.1 Hz, 2H), 7.33 (t, *J* = 7.5 Hz, 2H), 7.30 – 7.23 (m, 2H), 4.41 (q, *J* = 7.1 Hz, 2H), 4.29 (d, *J* = 7.1 Hz, 2H), 4.19 – 4.12 (m, 2H), 2.56 (t, *J* = 7.4 Hz, 2H), 2.21 (dt, *J* = 12.7, 7.5 Hz, 1H), 2.05 – 1.94 (m, 1H), 1.46 (s, 9H), 1.40 (t, *J* = 7.1 Hz, 3H). *The free N-H is not visible in the H-NMR.*

<sup>13</sup>C NMR (100 MHz, MeOD) δ 182.3, 174.9, 173.2, 166.0, 158.6, 145.2 (2C), 142.5, 142.5 (2C), 138.1, 135.9, 132.4 (2C), 128.8 (2C), 128.1 (2C), 126.2 (2C), 123.5 (2C), 120.9 (2C), 82.8, 68.0, 63.0, 55.9, 36.8, 28.6, 28.3 (3C), 28.2, 14.5.


LCMS (ESI) *m/z* [M+H]<sup>+</sup> 641.7

IR (neat, cm<sup>-1</sup>): 2980, 1712, 1626, 1543, 1478, 1449, 1368, 1346, 1274, 1153.

HRMS (ESI) *m/z* calcd for C<sub>35</sub>H<sub>36</sub>N<sub>4</sub>O<sub>8</sub> [M+H]<sup>+</sup>: 641,2606 found 641,2612.

**IS2**

(S)-3-(((tert-butoxycarbonyl)amino)-4-methoxy-4-oxobutanoyl)(3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)amide



$C_{18}H_{22}N_4O_6$   
**MW:** 390 g.mol<sup>-1</sup>  
**Yield:** 81%  
 Yellow solid

The product was obtained following the General Procedure A using iminosydnone **6a** (200 mg, 1.0 mmol, 1.0 equiv.), acid Boc-L-Asp-OMe (375 mg, 1.5 mmol, 1.5 equiv.), HATU (770 mg, 2.0 mmol, 2.0 equiv.) and DIPEA (523 mg, 4.1 mmol, 4.0 equiv.) to give the desired product in 81% yield (320 mg, 0.82 mmol).

<sup>1</sup>H NMR (400 MHz, MeOD) δ 8.69 (s, 1H), 8.04 – 7.98 (m, 2H), 7.84 – 7.69 (m, 3H), 4.57 (t, *J* = 5.7 Hz, 1H), 3.72 (s, 3H), 2.93 (t, *J* = 6.1 Hz, 2H), 1.44 (s, 9H). *The free N-H is not visible in the H-NMR.*

$^{13}\text{C}$  NMR (100 MHz, MeOD)  $\delta$  179.4, 174.8, 174.2, 157.8, 135.3, 134.5, 131.6 (2C), 123.4 (2C), 107.2, 80.7, 52.8, 52.2, 42.1, 28.7 (3C).


LCMS (ESI)  $m/z$   $[\text{M}+\text{H}]^+$  391.5.

IR (neat,  $\text{cm}^{-1}$ ): 2953, 1697, 1623, 1540, 1469, 1359, 1294, 1160, 841, 761, 557.

HRMS (ESI)  $m/z$  calcd for  $\text{C}_{18}\text{H}_{22}\text{N}_4\text{O}_6$   $[\text{M}+\text{H}]^+$ : 391.1612 . found 391.1619.

### IS3

*Benzoyl(3-(4-(ethoxycarbonyl)phenyl)-1,2,3-oxadiazol-3-ium-5-yl)amide*



$\text{C}_{18}\text{H}_{15}\text{N}_3\text{O}_4$   
MW: 337  $\text{g}\cdot\text{mol}^{-1}$   
Yield: 50%  
Yellow solid

The product was obtained following the General Procedure A using iminosydnone **6b** (108 mg, 0.4 mmol, 1.0 equiv.), benzoic acid (73 mg, 0.6 mmol, 1.5 equiv.), HATU (305 mg, 0.8 mmol, 2.0 equiv.) and DIPEA (272 mg, 1.6 mmol, 4.0 equiv.) to give the desired product in 50% yield (68 mg, 0.2 mmol).


$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.72 (s, 1H), 8.33 – 8.25 (m, 4H), 7.98 – 7.91 (m, 2H), 7.52 – 7.47 (m, 1H), 7.46 – 7.40 (m, 2H), 4.44 (q,  $J = 7.1$  Hz, 2H), 1.44 (t,  $J = 7.1$  Hz, 3H).

$^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  174.8, 174.5, 164.5, 136.9, 136.8, 135.0, 131.9 (2C), 131.9, 129.7 (2C), 128.2 (2C), 121.7 (2C), 104.7, 62.2, 14.4.

LCMS (ESI)  $m/z$   $[\text{M}+\text{H}]^+$  338.4.


IR ( $\text{cm}^{-1}$ ): 3195, 1720, 1631, 1580, 1552, 1439, 1321, 1295, 1275, 1105, 970, 856, 770, 735, 689.

HRMS (ESI)  $m/z$  calcd for  $\text{C}_{18}\text{H}_{15}\text{N}_3\text{O}_4$   $[\text{M}+\text{H}]^+$ : 338.1135 ; found: 338.1143.



**IS4**

(S)-(4-methoxy-4-oxo-3-(quinoline-2-carboxamido)butanoyl)(3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)amide



$C_{23}H_{19}N_5O_5$   
**MW:** 445 g.mol<sup>-1</sup>  
**Yield:** 54%  
 Yellow solid

To the solution of **IS2** (156 mg, 0.4 mmol, 1 equiv.) in DCM (8 mL) at 0 °C, a solution of HCl (4.0 M, 8 mL) in dioxane was added dropwise. The reaction was stirred at 0 °C for 2 hours before being concentrated under *vacuum*. The residue was then dissolved in DMF (10 mL). Quinaldic acid (104 mg, 0.6 mmol, 1.5 equiv.) was added followed by HATU (258 mg, 0.8 mmol, 2.0 equiv.). The reaction was stirred at room temperature for 20 min before cooled to -30 °C. DIPEA (0.782 mL, 1.6 mmol, 4.0 equiv.) was added and the mixture was warmed to room temperature and stirred during 6 hours. A saturated NH<sub>4</sub>Cl aqueous solution (15 mL) was added and the mixture was extracted with EtOAc (3 x 20 mL). Organic layers were combined, dried over MgSO<sub>4</sub> and filtered. Solvents were evaporated under vacuum and the crude product was purified by flash chromatography (heptane/ethyl acetate) on silica gel to give the desired product **IS4** in 54% yield over two steps (96 mg, 0.22 mmol).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.34 (d, *J* = 7.4 Hz, 1H), 8.53 (s, 1H), 8.27 (d, *J* = 0.9 Hz, 2H), 8.17 (d, *J* = 8.5 Hz, 1H), 7.86 – 7.56 (m, 8H), 5.13 (dt, *J* = 7.4, 5.1 Hz, 1H), 3.67 (s, 3H), 3.27 (ddd, *J* = 56.9, 16.4, 5.1 Hz, 2H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 178.8, 174.3, 172.0, 164.5, 149.8, 146.7, 137.3, 133.8, 133.4, 130.7 (2C), 130.3, 129.9, 129.4, 127.9, 127.7, 121.6 (2C), 118.9, 104.9, 52.8, 51.9, 37.2.


LCMS (ESI) *m/z* [M+H]<sup>+</sup> 446.5.

HRMS (ESI) *m/z* calcd for C<sub>23</sub>H<sub>19</sub>N<sub>5</sub>O<sub>5</sub> [M+H]<sup>+</sup> 446,1459; found: 446,1465.

IR (neat, cm<sup>-1</sup>) 3381, 3133, 1734, 1674, 1630, 1556, 1498, 1470, 1367, 1316, 1215, 1186.

**IS5**

(S)-(4-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-5-oxopentanoyl(3-(3-phenylpropyl)-1,2,3-oxadiazol-3-ium-5-yl)amide



$C_{35}H_{38}N_4O_6$   
**MW:** 610 g.mol<sup>-1</sup>  
**Yield:** 95%  
 White solid

The product was obtained following the General Procedure A using iminosydnone **6c** (115 mg, 0.48 mmol, 1.0 equiv.), Fmoc-Glu-O<sup>t</sup>Bu (306 mg, 0.72 mmol, 1.5 equiv.), HATU (365 mg, 0.96 mmol, 2.0 equiv.) and DIPEA (279 mg, 2.16 mmol, 4.5 equiv.) to give the desired product in 95% yield (278 mg, 0.46 mmol).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 7.94 (s, 1H), 7.75 (d, *J* = 7.5 Hz, 2H), 7.65 – 7.58 (m, 2H), 7.38 (t, *J* = 7.5 Hz, 2H), 7.35 – 7.27 (m, 4H), 7.24 (d, *J* = 7.4 Hz, 1H), 7.14 (d, *J* = 7.2 Hz, 2H), 5.96 (d, *J* = 7.8 Hz, 1H), 4.44 – 4.27 (m, 5H), 4.21 (t, *J* = 7.3 Hz, 1H), 2.72 (t, *J* = 7.2 Hz, 2H), 2.67 – 2.56 (m, 2H), 2.34 (dd, *J* = 14.4, 7.2 Hz, 2H), 2.28 – 2.20 (m, 1H), 2.09 (dt, *J* = 14.3, 7.2 Hz, 1H), 1.48 (s, 9H).

**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)** δ 181.9, 173.8, 171.6, 156.1, 144.0, 141.2 (2C), 138.4, 128.9 (2C), 128.4 (2C), 127.6 (2C), 127.1 (2C), 127.0 (2C), 125.3 (2C), 119.9 (2C), 105.8, 82.0, 67.0, 54.5, 52.7, 47.2, 38.6, 36.0, 32.0, 30.1, 28.0 (3C).


**LCMS (ESI) *m/z* [M+H]<sup>+</sup>** 611.8.

**IR (cm<sup>-1</sup>)** : 3295, 2975, 1717, 1626, 1551, 1449, 1400, 1368, 1330, 1247, 1152, 1104, 1081, 1050, 956, 845, 759, 740, 700, 645, 621, 559, 539.

**HRMS (ESI) *m/z* calcd for C<sub>35</sub>H<sub>38</sub>N<sub>4</sub>O<sub>6</sub> [M+H]<sup>+</sup>**: 611.2864 ; found: 611.2874.

#### IS11

*(2-(6-methoxynaphthalen-2-yl)propanoyl)(3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)amide*



C<sub>22</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>  
**MW**: 373 g.mol<sup>-1</sup>  
**Yield**: Quant.  
Yellow solid

The product was obtained following the General Procedure A using iminosydnone **6a** (50 mg, 0.25 mmol, 1.0 equiv.), DL-naproxen (87 mg, 0.38 mmol, 1.5 equiv.), HATU (184 mg, 0.51 mmol, 2.0 equiv.) and DIPEA (131 mg, 1.0 mmol, 4.0 equiv.) to give the desired product in 99% yield (94 mg, 0.25 mmol).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.38 (s, 1H), 7.79 – 7.71 (m, 3H), 7.68 (dd, *J* = 8.1, 5.6 Hz, 3H), 7.61 (t, *J* = 7.5 Hz, 2H), 7.54 (dd, *J* = 8.5, 1.3 Hz, 1H), 7.11 – 7.06 (m, 2H), 4.07 (q, *J* = 7.1 Hz, 1H), 3.88 (s, 3H), 1.63 (d, *J* = 7.1 Hz, 3H).


**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)** δ 184.0, 174.2, 157.4, 138.1, 133.9, 133.6, 133.2, 130.7 (2C), 129.4, 129.2, 127.0, 126.9, 126.1, 121.6 (2C), 118.6, 105.7, 104.5, 55.4, 50.1, 19.0.

**LCMS (ESI) *m/z* [M+H]<sup>+</sup>** 374.9.

**IR (cm<sup>-1</sup>)** : 2934, 1731, 1605, 1548, 1470, 1391, 1359, 1265, 1230, 1214, 1175, 1081, 1028, 970, 927, 842, 764, 686, 558, 478.

**HRMS (ESI) *m/z* calcd for C<sub>22</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup>**: 374.1499 ; found: 374.1505.



**IS12a***(S)*-4-((*tert*-butoxycarbonyl)amino)-5-methoxy-5-oxopentanoyl(3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)amide

$C_{19}H_{24}N_4O_6$   
**MW:** 404 g.mol<sup>-1</sup>  
**Yield:** 29%  
 Yellow solid

**IS6a** (647 mg, 3.3 mmol, 1.0 equiv.) was dissolved in DMF (65 mL) and Boc-L-glutamic acid  $\alpha$ -methyl-ester (1.31 g, 5.0 mmol, 1.5 equiv.) was added followed by HATU (2.35 g, 7.2 mmol, 2.0 equiv.). The reaction was stirred at room temperature for 20 min before cooled to -20 °C. DIPEA (1.70 g, 2.18 mL, 13.2 mmol, 4.0 equiv.) was added and the mixture was warmed to room temperature and stirred for 6 hours. A NH<sub>4</sub>Cl solution was added and the mixture was extracted with EtOAc. Organic layers were combined and evaporated to give the crude product, which was purified by chromatographic column to give the desired product as a yellow solid in 29% yield (386.6 mg, 0.96 mmol).


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.45 (s, 1H), 7.83 (d,  $J$  = 7.6 Hz, 2H), 7.77 – 7.63 (m, 3H), 5.43 (d,  $J$  = 8.0 Hz, 1H), 4.36 (dd,  $J$  = 13.1, 8.0 Hz, 1H), 3.73 (s, 3H), 2.67 – 2.55 (m, 2H), 2.22 (m, 1H), 2.03 (m, 1H), 1.42 (s, 9H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  181.8, 173.8, 173.4, 155.6, 133.9, 133.4, 130.8 (2C), 121.7 (2C), 104.5, 79.8, 53.5, 52.4, 36.0, 28.5 (3C), 28.4.

LCMS (ESI)  $m/z$  [M+H]<sup>+</sup> 405.4

IR (cm<sup>-1</sup>) : 2925, 1735, 1698, 1625, 1541, 1470, 1361, 1162, 839, 738, 557.

HRMS (ESI)  $m/z$  calcd for C<sub>19</sub>H<sub>24</sub>N<sub>4</sub>O<sub>6</sub> [M+H]<sup>+</sup>: 405.1774 ; found 405.1776.

**IS12***(S)*-5-methoxy-5-oxo-4-(2-phenylacetamido)pentanoyl(3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)amide

$C_{22}H_{22}N_4O_5$   
**MW:** 422 g.mol<sup>-1</sup>  
**Yield:** 9%  
 Yellow solid

To a solution of **IS12a** (333 mg, 0.83 mmol, 1.0 equiv.) in DCM (15 mL) was added HCl (4 M in dioxane, 15 mL) and the mixture was stirred overnight and evaporated. The product was redissolved in THF (5 mL) and a saturated aqueous solution of sodium carbonate (4 mL) was added at 0 °C. Phenyl acetyl chloride (192 mg, 1.24 mmol, 1.5 equiv.) was added slowly and the reaction was stirred for 3 hours until completion. The mixture was evaporated and the residue was dissolved in ethyl acetate and

washed with a saturated aqueous solution of sodium carbonate to give the desired product in 9% yield (31 mg, 0,074 mmol).


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.31 (s, 1H), 7.84 – 7.78 (m, 2H), 7.77 – 7.65 (m, 3H), 7.28 (d, *J* = 4.4 Hz, 3H), 7.23 – 7.17 (m, 1H), 6.91 (d, *J* = 7.2 Hz, 1H), 4.59 (td, *J* = 7.8, 5.0 Hz, 1H), 3.70 (s, 3H), 3.60 (s, 2H), 2.63 – 2.46 (m, 2H), 2.19 (m, 1H), 2.04 (m, 1H). *The free N-H is not visible in the H-NMR.*

**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)** δ 181.7, 173.7, 172.8, 171.1, 135.0, 133.9, 133.4, 130.8 (2C), 129.6 (2C), 128.9 (2C), 127.1, 121.7 (2C), 104.5, 52.6, 52.4, 43.6, 36.0, 27.3.

**LCMS (ESI) *m/z* [M+H]<sup>+</sup>** 423.3

#### IS13

*(E)*-4-(((4-chlorophenyl)(5-fluoro-2-hydroxyphenyl)methylene)amino)butanoyl(3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)amide



C<sub>25</sub>H<sub>20</sub>ClFN<sub>4</sub>O<sub>3</sub>

**MW:** 478 g.mol<sup>-1</sup>

**Yield:** 46%

Yellow solid

The product was obtained following the General Procedure A using iminosydnone **6a** (66 mg, 0.34 mmol, 1.0 equiv.), progabide acid (169 mg, 0.50 mmol, 1.5 equiv.), HATU (216 mg, 0.67 mmol, 2.0 equiv.) and DIPEA (174 mg, 1.35 mmol, 4.0 equiv.) to give the desired product with 46% yield (73 mg, 0.15 mmol).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.30 (s, 1H), 7.79 (dd, *J* = 7.3, 1.8 Hz, 2H), 7.77 – 7.64 (m, 3H), 7.50 – 7.44 (m, 2H), 7.22 – 7.15 (m, 2H), 6.93 (td, *J* = 8.5, 2.9 Hz, 1H), 6.85 (dd, *J* = 8.9, 4.8 Hz, 1H), 6.43 (dd, *J* = 9.7, 2.8 Hz, 1H), 3.42 (t, *J* = 6.8 Hz, 2H), 2.55 (t, *J* = 7.1 Hz, 2H), 2.10 (p, *J* = 7.0 Hz, 2H).

**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)** δ 182.2, 173.7, 172.2, 159.3, 154.4 (d, <sup>1</sup>*J*<sub>C-F</sub> = 235.0 Hz), 135.4, 134.0, 133.3, 131.9, 130.7 (2C), 129.3 (2C), 129.0 (2C), 121.7 (2C), 119.6 (d, <sup>2</sup>*J*<sub>C-F</sub> = 23.6 Hz), 119.3 (d, <sup>4</sup>*J*<sub>C-F</sub> = 5.7 Hz), 118.8 (d, <sup>3</sup>*J*<sub>C-F</sub> = 7.2 Hz), 116.5 (d, <sup>2</sup>*J*<sub>C-F</sub> = 24.3 Hz), 104.3, 51.8, 38.0, 27.1.


**LCMS (ESI) *m/z* [M+H]<sup>+</sup>** 479.3.

**IR (cm<sup>-1</sup>)** : 2941, 1614, 1543, 1490, 1470, 1361, 1256, 1175, 1090, 1016, 844, 765, 684, 558.

**HRMS (ESI) *m/z* calcd for C<sub>25</sub>H<sub>20</sub>ClFN<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup>**: 479.1281 ; found: 479.1286.

**IS15**

(3-(4-(ethoxycarbonyl)phenyl)-1,2,3-oxadiazol-3-ium-5-yl)(1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carbonyl)amide



C<sub>36</sub>H<sub>33</sub>N<sub>7</sub>O<sub>7</sub>

**MW:** 675 g.mol<sup>-1</sup>

**Yield:** 46%

Yellow solid

The product was obtained following the General Procedure A using iminosydnone **6b** (66 mg, 0.25 mmol, 1.0 equiv.), Apixaban (169 mg, 0.37 mmol, 1.5 equiv.), HATU (186 mg, 0.49 mmol, 2.0 equiv.) and DIPEA (127 mg, 0.98 mmol, 4.0 equiv.) to give the desired product with 46% yield (76 mg, 0.11 mmol).


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.66 (s, 1H), 8.36 – 8.29 (m, 2H), 7.95 (m, 2H), 7.53 – 7.49 (m, 2H), 7.35 (m, 2H), 7.26 (m, 2H), 6.89 – 6.86 (m, 2H), 4.45 (q, *J* = 7.1 Hz, 2H), 4.12 (t, *J* = 6.7 Hz, 2H), 3.79 (s, 3H), 3.57 (t, *J* = 4.8 Hz, 2H), 3.44 (t, *J* = 6.7 Hz, 2H), 2.55 (m, 2H), 1.96 – 1.88 (m, 4H), 1.44 (t, *J* = 7.1 Hz, 3H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 174.4, 170.3, 169.8, 164.5, 159.6, 157.8, 145.1, 141.3, 140.4, 136.7, 135.1, 133.1, 132.9, 131.9 (2C), 127.2 (2C), 126.8 (2C), 126.7, 126.3 (2C), 121.8 (2C), 113.5 (2C), 105.1, 62.2, 55.6, 51.7, 51.3, 32.9, 23.6, 22.3, 21.5, 14.4.

**LCMS (ESI) *m/z*** [M+H]<sup>+</sup> 676.6.

## 2. Procedure and analytical data for chlorination of iminosydnone

### General procedure B: chlorination of iminosydnone substrates




To a solution of iminosydnone (1.0 equiv) in MeCN (0.5 M) was added *t*BuOCl (2.0 equiv). The mixture was stirred at room temperature. The reaction was followed by LCMS. Once the reaction has reached completion (ca. 0.5 to 1 hour), the solvent was evaporated under reduced pressure to give the crude product. The crude product was then purified by chromatographic column on gel to give the desired Cl-imsyd. product (heptane/ethyl acetate). The product of chlorination being not so stable in system, quick work up and purification are essential.

### Attention: Safety precautions

*t*BuOCl is known to be unstable when exposed to intense light. To avoid vigorous decomposition, this reagent should be handled only in dim light and should not be heated above its boiling point or be exposed to rubber.

### IS1'

*(S)*-4-(((9*H*-fluoren-9-yl)methoxy)carbonyl)amino)-5-(*tert*-butoxy)-5-oxopentanoyl(4-chloro-3-(4-(propionyloxy)phenyl)-1,2,3-oxadiazol-3-ium-5-yl)amide



C<sub>35</sub>H<sub>35</sub>ClN<sub>4</sub>O<sub>8</sub>  
MW: 675 g.mol<sup>-1</sup>  
Yield: 83%  
Orange oil

The product was obtained using general procedure **B** from the non-chlorinated iminosydnone substrate **IS1** (35 mg, 55 μmol, 1 equiv.) and *t*BuOCl (6.8 μL, 60 μmol, 1.1 equiv.). The crude product was purified by column chromatography (SiO<sub>2</sub>, EtOAc/Hept, 6/4) to afford the desired product as an orange oil in 83% yield (30 mg, 44 μmol).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.32 (d, *J* = 8.7 Hz, 2H), 7.71 (dd, *J* = 22.6, 8.0 Hz, 4H), 7.61 (dd, *J* = 7.3, 3.7 Hz, 2H), 7.37 (t, *J* = 7.4 Hz, 2H), 7.34 – 7.27 (m, 2H), 5.81 (d, *J* = 8.1 Hz, 1H), 4.45 (q, *J* = 7.1 Hz, 2H), 4.41 – 4.28 (m, 3H), 4.22 (t, *J* = 7.2 Hz, 1H), 2.77 – 2.57 (m, 2H), 2.29 (dt, *J* = 13.9, 7.2 Hz, 1H), 2.12 (td, *J* = 14.7, 7.9 Hz, 1H), 1.49 (s, 9H), 1.43 (t, *J* = 7.1 Hz, 3H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 180.6, 171.7, 164.5, 163.0, 156.2, 144.1 (2C), 141.4 (2C), 135.1, 134.9, 131.6 (2C), 127.7 (2C), 127.2 (2C), 125.4 (2C), 124.9 (2C), 120.0 (2C), 105.8, 82.1, 67.1, 62.3, 54.6, 47.3, 36.2, 28.2 (3C), 28.1, 14.4.


LCMS (ESI) *m/z* [M+H]<sup>+</sup> 675.5.

IR (cm<sup>-1</sup>): 2934, 1615, 1470, 1372, 1237, 1155, 1096, 976, 860, 764, 629.

HRMS (ESI) *m/z* calcd for C<sub>35</sub>H<sub>35</sub>ClN<sub>4</sub>O<sub>8</sub> [M+H]<sup>+</sup>: 675.2216; found: 675.2216.

**IS2'**

*(S)*-(3-((*tert*-butoxycarbonyl)amino)-4-methoxy-4-oxobutanoyl)(4-chloro-3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)amide



C<sub>18</sub>H<sub>21</sub>ClN<sub>4</sub>O<sub>6</sub>  
**MW:** 425 g.mol<sup>-1</sup>  
**Yield:** 81%  
 Yellow solid

The product was obtained using general procedure A from the non-chlorinated iminosydnone substrate **IS2** (75 mg, 192 μmol, 1 equiv.) and *t*BuOCl (44.0 μL, 384 μmol, 2 equiv.). The crude product was purified by column chromatography (SiO<sub>2</sub>, EtOAc/Hept, 6/4) to afford the desired product as yellow solid in 81% yield (66 mg, 156 μmol).

<sup>1</sup>H NMR (400 MHz, MeOD) δ 7.87 – 7.80 (m, 3H), 7.79 – 7.73 (m, 2H), 4.59 (t, *J* = 5.6 Hz, 1H), 3.74 (s, 3H), 3.01 – 2.90 (m, 2H), 1.44 (s, 9H). *The free N-H is not visible in the H-NMR.*

<sup>13</sup>C NMR (100 MHz, MeOD) δ 179.1, 174.1, 166.0, 157.8, 134.5, 133.3, 131.4 (2C), 126.4 (2C), 109.4, 80.7, 52.8, 52.2, 42.5, 28.7 (3C).


LCMS (ESI) *m/z* [M+H]<sup>+</sup> 425.6.

HRMS (ESI) *m/z* calcd for C<sub>18</sub>H<sub>21</sub>ClN<sub>4</sub>O<sub>6</sub>[M+H]<sup>+</sup>: 425.1222; found: 425.1224.

IR (cm<sup>-1</sup>): 3425, 2978, 1704, 1581, 1495, 1379, 1209, 1162, 1059, 1027, 843, 765, 689, 558.

**IS3'**

*Benzoyl*(4-chloro-3-(4-(ethoxycarbonyl)phenyl)-1,2,3-oxadiazol-3-ium-5-yl)amide



C<sub>18</sub>H<sub>14</sub>ClN<sub>3</sub>O<sub>4</sub>  
**MW:** 372 g.mol<sup>-1</sup>  
**Yield:** 99%  
 Yellow solid

The product was obtained using general procedure B from the non-chlorinated iminosydnone substrate **IS3** (32.3 mg, 96 μmol, 1 equiv.) and *t*BuOCl (40 μL, 354 μmol, 3.7 equiv.). The crude product was purified by column chromatography (SiO<sub>2</sub>, EtOAc/Hept, 3/7) to afford the desired product as a yellow solid in 99% yield (35.4 mg, 96 μmol).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.41 – 8.35 (m, 2H), 8.33 – 8.28 (m, 2H), 7.83 – 7.75 (m, 2H), 7.54 – 7.42 (m, 3H), 4.47 (q, *J* = 7.1 Hz, 2H), 1.45 (t, *J* = 7.1 Hz, 3H).


<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 172.9, 164.5, 164.0, 136.7, 136.6, 135.1, 132.1, 131.7 (2C), 130.0 (2C), 128.2 (2C), 125.0 (2C), 106.3, 62.3, 14.4.

LCMS (ESI) *m/z* [M+H]<sup>+</sup> 372.2.

IR (cm<sup>-1</sup>) : 2930, 1716, 1639, 1438, 1311, 1358, 1278, 1220, 1164, 1107, 1050, 1015, 913, 769, 715.  
HRMS (ESI) *m/z* calcd for C<sub>18</sub>H<sub>14</sub>ClN<sub>3</sub>O<sub>4</sub> [M+H]<sup>+</sup>: 372.0746; found: 372.0789.

**IS4'**

(*S*)-(4-chloro-3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)(4-methoxy-4-oxo-3-(quinoline-2-carboxamido)butanoyl)amide



C<sub>23</sub>H<sub>18</sub>ClN<sub>5</sub>O<sub>5</sub>  
MW: 479 g.mol<sup>-1</sup>  
Yield: 85%  
Yellow solid

The product was obtained using general procedure **B** from the non-chlorinated iminosydnone substrate **IS4** (59.0 mg, 132 μmol, 1 equiv.) and *t*BuOCl (30.0 μL, 265 μmol, 2 equiv.). The crude product was purified by column chromatography (SiO<sub>2</sub>, EtOAc/Hept, 4/6) to afford the desired product as a yellow solid in 85% yield (53 mg, 112 μmol).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.31 (d, *J* = 8.9 Hz, 1H), 8.28 (d, *J* = 1.2 Hz, 2H), 8.17 – 8.10 (m, 1H), 7.85 (dd, *J* = 8.2, 0.8 Hz, 1H), 7.76 – 7.61 (m, 6H), 7.58 (ddd, *J* = 8.1, 7.0, 1.1 Hz, 1H), 5.21 (dt, *J* = 9.0, 4.5 Hz, 1H), 3.79 (s, 3H), 3.42 (dd, *J* = 17.2, 4.8 Hz, 1H), 3.17 (dd, *J* = 17.2, 4.3 Hz, 1H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 177.8, 172.1, 164.4, 163.6, 149.5, 146.6, 137.3, 133.3, 131.8, 130.4 (2C), 130.1, 129.9, 129.3, 127.9, 127.6, 124.7 (2C), 119.0, 106.2, 52.6, 49.4, 41.8.


LCMS (ESI) *m/z* [M+H]<sup>+</sup> 480.7.

IR (cm<sup>-1</sup>) : 3386, 2924, 1744, 1673, 1583, 1498, 137, 1204, 1061, 845, 769, 698.

HRMS (ESI) *m/z* calcd for C<sub>23</sub>H<sub>18</sub>ClN<sub>5</sub>O<sub>5</sub>[M+H]<sup>+</sup>: 480.1075; found: 480.1078.

**IS5'**

(*S*)-(4-(((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-5-oxopentanoyl(3-(3-phenylpropyl)-1,2,3-oxadiazol-3-ium-5-yl)amide



C<sub>35</sub>H<sub>37</sub>ClN<sub>4</sub>O<sub>6</sub>  
MW: 644 g.mol<sup>-1</sup>  
Yield: 42%  
Yellow solid

The product was obtained using general procedure **B** from the non-chlorinated iminosydnone substrate **IS5** (85 mg, 139 μmol, 1 equiv.) and *t*BuOCl (35 μL, 306 μmol, 2.2 equiv.). The crude product was purified by column chromatography (SiO<sub>2</sub>, 100% EtOAc) to afford the desired product as a yellow solid in 42% yield (38 mg, 58 μmol).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.74 (d, *J* = 7.5 Hz, 2H), 7.65 – 7.56 (m, 2H), 7.38 (t, *J* = 7.4 Hz, 2H), 7.31 (q, *J* = 6.7 Hz, 4H), 7.16 (d, *J* = 7.2 Hz, 2H), 5.87 (d, *J* = 7.8 Hz, 1H), 4.38 (t, *J* = 7.3 Hz, 2H), 4.31 (dd, *J* = 17.6, 7.4 Hz, 2H), 4.21 (t, *J* = 7.2 Hz, 1H), 2.75 (t, *J* = 7.3 Hz, 2H), 2.62 (dd, *J* = 16.4, 7.6 Hz, 2H), 2.38 – 2.29 (m, 2H), 2.28 – 2.20 (m, 1H), 2.10 (dd, *J* = 14.7, 7.6 Hz, 1H), 2.00 – 1.85 (m, 2H), 1.48 (s, 9H).

The product is not stable enough in solvent to afford a <sup>13</sup>C NMR spectrum.


**LCMS (ESI)  $m/z$  [M+H]<sup>+</sup>** 645.8.

**IR (cm<sup>-1</sup>)** : 2977, 2929, 1715, 1589, 1450, 1395, 1154, 1044, 842, 744, 557.

**HRMS (ESI)  $m/z$**  calcd for C<sub>35</sub>H<sub>37</sub>ClN<sub>4</sub>O<sub>6</sub> [M+H]<sup>+</sup>: 645.2474; found: 645.2471.

**IS6'**

*(3-benzyl-4-chloro-1,2,3-oxadiazol-3-ium-5-yl)(morpholine-4-carbonyl)amide*



C<sub>14</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>3</sub>  
**MW:** 322 g.mol<sup>-1</sup>  
**Yield:** 65%  
White solid

The product was obtained using general procedure **B** from the non-chlorinated iminosydnone substrate **IS6** (17.5 mg, 61 μmol, 1 equiv.) and *t*BuOCl (27.5 μL, 243 μmol, 4 equiv.). The crude product was purified by column chromatography (SiO<sub>2</sub>, EtOAc/MeOH, 9/1) to afford the desired product as a white solid in 65% yield (12 mg, 40 μmol).

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 7.47 – 7.35 (m, 5H), 5.47 – 5.42 (m, 2H), 3.70-3.58 (m, 8H).

**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)** δ 161.8, 158.9, 130.3, 129.9, 129.6 (2C), 128.9 (2C), 102.4, 67.1 (2C), 55.2, 46.1, 43.1.


**IR (cm<sup>-1</sup>)** : 2854, 1635, 1454, 1414, 1275, 1236, 1179, 1113, 1026, 852, 713, 517

**LCMS (ESI)  $m/z$  [M+H]<sup>+</sup>** 324.

**HRMS (ESI)  $m/z$**  calcd for C<sub>14</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup>: 323.0905; found: 323.0905.

**IS7'**

*((tert-butoxycarbonyl)glycyl)(4-chloro-3-(4-(propionyloxy)phenyl)-1,2,3-oxadiazol-3-ium-5-yl)amide*



C<sub>19</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>6</sub>  
**MW:** 453 g.mol<sup>-1</sup>  
**Yield:** 80%  
Yellow solid

The product was obtained using general procedure **B** from the non-chlorinated iminosydnone substrate **IS7** (92 mg, 219 μmol, 1 equiv.) and *t*BuOCl (60 μL, 526 μmol, 2.4 equiv.). The crude product was purified by column chromatography (SiO<sub>2</sub>, EtOAc/Hept, 6/4) to afford the desired product as a yellow solid in 80% yield (82 mg, 175 μmol).


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)** δ 8.27 (d, *J* = 8.7 Hz, 2H), 7.68 (d, *J* = 8.7 Hz, 2H), 5.60 (s, 1H), 5.01 (s, 1H), 4.39 (q, *J* = 7.1 Hz, 2H), 3.39 – 3.29 (m, 2H), 3.24 (d, *J* = 5.4 Hz, 2H), 1.41 – 1.34 (m, 12H).

*The product is not stable enough in solvent to afford a <sup>13</sup>C NMR spectrum.*

**LCMS (ESI)  $m/z$  [M+H]<sup>+</sup>** 454.8.

**IR (cm<sup>-1</sup>)** : 2934, 1615, 1470, 1372, 1237, 1155, 1096, 976, 860, 764, 629.

**HRMS (ESI)  $m/z$**  calcd for C<sub>19</sub>H<sub>24</sub>ClN<sub>5</sub>O<sub>6</sub> [M+H]<sup>+</sup>: 454.1488 ; found: 454.1493.

**IS8'***(tert-butoxycarbonyl)(4-chloro-3-(p-tolyl)-1,2,3-oxadiazol-3-ium-5-yl)amide*C<sub>14</sub>H<sub>16</sub>ClN<sub>3</sub>O<sub>3</sub>**MW:** 309 g.mol<sup>-1</sup>**Yield:** 61%

White solid

The product was obtained using general procedure **B** from the non-chlorinated iminosydnone substrate **IS8** (30.0 mg, 109 μmol, 1 equiv.) and *t*BuOCl (24.7 μL, 218 μmol, 2 equiv.). The crude product was purified by column chromatography (SiO<sub>2</sub>, EtOAc/Hept, 6/4) to afford the desired product as a white solid in 61% yield (27 mg, 66 μmol).


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.50 – 7.48 (m, 2H), 7.43 (d, *J* = 8.2 Hz, 2H), 2.47 (s, 3H), 1.52 (s, 9H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 163.2, 158.4, 144.0, 130.8 (2C), 126.2, 124.4 (2C), 79.8, 28.2 (3C), 21.5.

The C<sub>4</sub> of the iminosydnone is not visible in C-NMR (too low signal).

IR (cm<sup>-1</sup>): 2976, 2927, 1749, 1668, 1621, 1509, 1452, 1366, 1283, 1220, 1146, 1050, 1028, 879, 820, 577, 525.

HRMS (ESI) *m/z* calcd for C<sub>14</sub>H<sub>16</sub>ClN<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup>: 310.0959; found: 310.0964.

**IS9'***(4-chloro-3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)((2S,3R,4R,5S,6R)-2,4,5-triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-3-yl)carbamoyl)amide*C<sub>23</sub>H<sub>25</sub>ClN<sub>4</sub>O<sub>11</sub>**MW:** 568 g.mol<sup>-1</sup>**Yield:** 88%

Yellow solid

The product was obtained using general procedure **B** from the non-chlorinated iminosydnone substrate **IS9** (59.0 mg, 110 μmol, 1 equiv.) and *t*BuOCl (30.0 μL, 265 μmol, 2.4 equiv.). The crude product was purified by column chromatography (SiO<sub>2</sub>, EtOAc/Hept, 2/8) to afford the desired product as a yellow solid in 88% yield (55 mg, 97 μmol).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.78 – 7.55 (m, 5H), 5.80 (d, *J* = 8.8 Hz, 1H), 5.45 – 5.24 (m, 2H), 5.12 (t, *J* = 9.6 Hz, 1H), 4.28 (dd, *J* = 12.4, 4.6 Hz, 1H), 4.18 – 4.06 (m, 2H), 3.85 (ddd, *J* = 10.0, 4.5, 2.1 Hz, 1H), 2.11 (s, 3H), 2.07 (s, 3H), 2.04 (s, 3H), 2.01 (s, 3H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 170.8, 170.7, 169.5, 169.5, 161.8, 159.1, 133.0, 132.0, 130.3 (2C), 124.7 (2C), 103.5, 92.7, 72.7, 72.6, 68.3, 61.8, 54.0, 21.0, 20.8, 20.7, 20.6.

LCMS (ESI) *m/z* [M+H]<sup>+</sup> 569.5.


HRMS (ESI) *m/z* calcd for C<sub>23</sub>H<sub>25</sub>ClN<sub>4</sub>O<sub>11</sub> [M+H]<sup>+</sup>: 569.1281; found: 569.1281.

IR (cm<sup>-1</sup>): 2968, 1748, 1645, 1505, 1368, 1222, 1073, 1043, 906, 772, 691.



**IS10'**

(4-chloro-3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)((((8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl)oxy)carbonyl)amide



$C_{27}H_{28}ClN_3O_4$   
**MW:** 493 g.mol<sup>-1</sup>  
**Yield:** 84%  
 Yellow solid

The product was obtained using general procedure **B** from the non-chlorinated iminosydnone substrate **IS10** (23.0 mg, 50 μmol, 1 equiv.) and *t*BuOCl (9.0 μL, 80 μmol, 1.6 equiv.). The crude product was purified by column chromatography (SiO<sub>2</sub>, EtOAc/Hept, 6/4) to afford the desired product as a yellow solid in 84% yield (21 mg, 42 μmol).

<sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 7.82 – 7.76 (m, 1H), 7.76 – 7.66 (m, 4H), 7.30 (d, *J* = 8.4 Hz, 1H), 6.94 (dd, *J* = 8.4, 2.5 Hz, 1H), 6.90 (d, *J* = 2.4 Hz, 1H), 3.74 – 3.66 (m, 1H), 2.93 – 2.82 (m, 2H), 2.39 – 2.32 (m, 1H), 2.25 (td, *J* = 11.1, 4.1 Hz, 1H), 2.15 – 2.04 (m, 1H), 1.97 – 1.87 (m, 2H), 1.76 – 1.66 (m, 1H), 1.57 – 1.50 (m, 2H), 1.49 – 1.47 (m, 1H), 1.45 (m, 1H), 1.41 – 1.37 (m, 1H), 1.37 – 1.33 (m, 1H), 1.33 – 1.29 (m, 1H), 1.26 – 1.18 (m, 1H), 0.78 (s, 3H).

<sup>13</sup>C NMR (101 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 164.9, 158.1, 150.2, 138.7, 138.1, 133.9, 132.4, 131.0 (2C), 126.6, 125.3 (2C), 122.3, 119.4, 106.3, 82.3, 50.7, 44.8, 43.8, 39.2, 37.3, 31.1, 30.2, 27.7, 26.9, 23.7, 11.4.


LCMS (ESI) *m/z* [M+H]<sup>+</sup> 495.1.

HRMS (ESI) *m/z* calcd for C<sub>27</sub>H<sub>28</sub>ClN<sub>3</sub>O<sub>4</sub>[M+H]<sup>+</sup>: 494.1841; found: 494.1841.

IR (cm<sup>-1</sup>): 2922, 1682, 1626, 1493, 1378, 1205, 1156, 1067, 767.

**IS11'**

(4-chloro-3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)(2-(6-methoxynaphthalen-2-yl)propanoyl)amide



$C_{22}H_{18}ClN_3O_3$   
**MW:** 407 g.mol<sup>-1</sup>  
**Yield:** 65%  
 Yellow solid

The product was obtained using general procedure **B** from the non-chlorinated iminosydnone substrate **IS11** (80.0 mg, 214 μmol, 1 equiv.) and *t*BuOCl (48.5 μL, 428 μmol, 2 equiv.). The crude product was purified by column chromatography (SiO<sub>2</sub>, EtOAc/Hept, 1/1) to afford the desired product as a yellow solid in 65% yield (57 mg, 139 μmol).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.38 (s, 1H), 8.14 (d, *J* = 8.8 Hz, 1H), 7.80 – 7.68 (m, 5H), 7.65 (t, *J* = 7.4 Hz, 3H), 7.24 (s, 1H), 4.07 (q, *J* = 7.1 Hz, 1H), 4.00 (s, 3H), 1.63 (d, *J* = 7.1 Hz, 3H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 183.1, 173.8, 152.3, 138.8, 133.8, 133.4, 131.0, 130.8 (2C), 129.8, 128.2, 128.0, 126.5, 123.7, 121.7 (2C), 116.8, 113.8, 104.8, 57.1, 49.8, 18.9.


IR (cm<sup>-1</sup>) : 2924, 1635, 1599, 1545, 1468, 1357, 1274, 1176, 1070, 965, 847, 752, 558

LCMS (ESI) *m/z* [M+H]<sup>+</sup> 409.0.

HRMS (ESI) *m/z* calcd for C<sub>22</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup>: 408.1109; found: 408.1109.

### IS13'

(*E*)-(4-chloro-3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)(4-(((4-chlorophenyl)(5-fluoro-2-hydroxyphenyl)methylene)amino)butanoyl)amide



A solution of substrate **IS13** (60 mg, 0.126 mmol, 1.0 equiv.) in dry MeCN (0.5 mL) was stirred under inert atmosphere. Then trimethylsilyl 2,2,2-trifluoro-*N*-(trimethylsilyl)acetimidate (50  $\mu$ L, 0.188 mmol, 1.5 equiv.) was added to the reaction dropwise at room temperature. Then the reaction was heated to 60 °C and stirred overnight. After removing the solvent under reduced pressure, the afforded crude product was used in the following step without further purification.

The TMS protected substrate was dissolved in 8 mL MeCN, then *t*BuOCl (29  $\mu$ L, 0.252 mmol, 2.0 equiv.) was added in one portion. The reaction was stirred at room temperature. The reaction was stopped after 45 mins. The solvent was evaporated under reduced pressure to give the crude product. Then the crude product was treated with HCl dioxane solution (1.0 M, 5.0 equiv) in MeCN for overnight. The reaction was concentrated and purified by column chromatography gave the desired 4-Cl-imSyd in 42% yield (35 mg, 0.053 mmol).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.76 (ddd, *J* = 6.2, 3.8, 1.4 Hz, 1H), 7.73 – 7.61 (m, 4H), 7.54 – 7.46 (m, 2H), 7.21 – 7.15 (m, 2H), 6.98 (ddd, *J* = 9.0, 7.9, 3.1 Hz, 1H), 6.90 (dd, *J* = 9.0, 4.8 Hz, 1H), 6.43 (dd, *J* = 9.7, 3.1 Hz, 1H), 3.42 (t, *J* = 6.9 Hz, 2H), 2.59 (t, *J* = 7.2 Hz, 2H), 2.10 (p, *J* = 7.1 Hz, 2H). The free O-H is not visible in the <sup>1</sup>H-NMR.


The product is not stable enough in solvent to afford a <sup>13</sup>C NMR spectrum.

LCMS (ESI) *m/z* [M+H]<sup>+</sup> 514.6.

HRMS (ESI) *m/z* calcd for C<sub>25</sub>H<sub>19</sub>Cl<sub>2</sub>FN<sub>4</sub>O<sub>3</sub> [M+H]<sup>+</sup>: 513.0897; found: 513.0898.

**IS12'**

*(S)*-4-(((9*H*-fluoren-9-yl)methoxy)carbonyl)amino)-5-(*tert*-butoxy)-5-oxopentanoyl(4-chloro-3-(4-(propionyloxy)phenyl)-1,2,3-oxadiazol-3-ium-5-yl)amide



$C_{23}H_{15}ClN_4O_2$   
**MW:** 414 g.mol<sup>-1</sup>  
**Yield:** 80%  
 Yellow solid

The product was obtained using general procedure **B** from the non-chlorinated iminosydnone substrate **IS14** (28.7 mg) and *t*BuOCl (18  $\mu$ L). The crude product was purified by column chromatography (SiO<sub>2</sub>, Hept/EtOAc, 6/4 to 100% EtOAc) to afford the desired product as an orange oil in 80% yield (25 mg, 60  $\mu$ mol).

<sup>1</sup>H NMR (400 MHz, MeOD)  $\delta$  7.82 – 7.65 (m, 5H), 7.51 – 7.26 (m, 8H), 6.97 (d, *J* = 1.6 Hz, 2H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  161.8, 158.8, 142.1, 141.2, 134.4, 134.2, 132.9 (2C), 132.2, 130.9, 130.3 (2C), 129.7, 129.2, 129.2, 129.0, 128.8, 128.4, 127.0, 126.7, 124.7 (2C), 104.0.


LCMS (ESI) *m/z* [M+H]<sup>+</sup> 415.9.

IR (cm<sup>-1</sup>): 2934, 1615, 1470, 1372, 1237, 1155, 1096, 976, 860, 764, 629.

HRMS (ESI) *m/z* calcd for C<sub>23</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup>: 415.0956; found: 415.0958.

**IS14'**

*(4-chloro-3-(4-(ethoxycarbonyl)phenyl)-1,2,3-oxadiazol-3-ium-5-yl)(1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1*H*-pyrazolo[3,4-*c*]pyridine-3-carbonyl)amide*



$C_{36}H_{32}ClN_7O_7$   
**MW:** 709 g.mol<sup>-1</sup>  
**Yield:** 59%  
 Yellow solid

The product was obtained using general procedure **B** from the non-chlorinated iminosydnone substrate **IS15** (33.0 mg) and *t*BuOCl (9.0  $\mu$ L). The crude product was purified by column chromatography (SiO<sub>2</sub>, EtOAc/Hept, 6/4) to afford the desired product as a yellow solid in 59% yield (35 mg, 49  $\mu$ mol).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.39 – 8.33 (m, 2H), 7.81 – 7.75 (m, 2H), 7.54 – 7.49 (m, 2H), 7.38 – 7.34 (m, 2H), 7.25 – 7.23 (m, 2H), 6.91 – 6.88 (m, 2H), 4.46 (q, *J* = 7.1 Hz, 2H), 4.13 (t, *J* = 6.7 Hz, 2H), 3.80 (s, 3H), 3.59 (t, *J* = 5.3 Hz, 2H), 3.46 (t, *J* = 6.7 Hz, 2H), 2.55 (t, *J* = 5.5 Hz, 2H), 1.94 – 1.91 (m, 4H), 1.44 (t, *J* = 7.1 Hz, 3H).

<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 170.3, 167.9, 164.6, 164.5, 159.7, 157.8, 144.8, 141.3, 140.3, 135.2, 134.9, 133.1, 133.0, 131.7 (2C), 127.2 (2C), 127.1, 126.9, 126.8 (2C), 126.3 (2C), 125.0 (2C), 113.6 (2C), 62.3, 55.6, 51.8, 51.3, 33.0, 23.6, 22.2, 21.5, 14.4.


LCMS (ESI) *m/z* [M+H]<sup>+</sup> 711.3.

IR (cm<sup>-1</sup>) : 2924, 1602, 1514, 1372, 1279, 1249, 1024, 837.

HRMS (ESI) *m/z* calcd for C<sub>36</sub>H<sub>32</sub>ClN<sub>7</sub>O<sub>7</sub> [M+H]<sup>+</sup>: 710.2125; found: 710.2138.

#### IS15'

(4-chloro-3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)(tosyl)amide



C<sub>15</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>3</sub>S  
MW: 349 g.mol<sup>-1</sup>  
Yield: 90%  
Yellow solid

The product was obtained using general procedure **B** from the non-chlorinated iminosydnone substrate **IS16** (17.0 mg) and *t*BuOCl (12.0 μL). The crude product was purified by column chromatography (SiO<sub>2</sub>, EtOAc/Hept, 6/4) to afford the desired product as a yellow solid in 90% yield (17 mg, 49 μmol).

<sup>1</sup>H NMR (400 MHz, Acetone-*d*<sub>6</sub>) δ 7.98 – 7.74 (m, 7H), 7.38 (d, *J* = 7.6 Hz, 2H), 2.42 (s, 3H).

<sup>13</sup>C NMR (100 MHz, Acetone-*d*<sub>6</sub>) δ 161.2, 143.4, 141.4, 134.1, 133.0, 131.2 (2C), 130.1 (2C), 127.8 (2C), 126.4 (2C), 106.8, 21.4.


LCMS (ESI) *m/z* [M+H]<sup>+</sup> 350.4.

HRMS (ESI) *m/z* calcd for C<sub>15</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>3</sub>S [M+H]<sup>+</sup>: 350.0361; found: 350.0361.

IR (cm<sup>-1</sup>) : 3073, 2926, 1614, 1467, 1370, 1301, 1289, 1150, 1091, 1007, 932, 858, 765, 688, 660, 610, 551.

**IS16'**

(4-chloro-3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)((4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)sulfonyl)amide



$C_{25}H_{17}ClF_3N_5O_3S$

**MW:** 559  $g \cdot mol^{-1}$

**Yield:** 77%

White solid

The product was obtained using general procedure **B** from the non-chlorinated iminosydnone substrate **IS17** (16.0 mg) and *t*BuOCl (6.5  $\mu$ L). The crude product was purified by column chromatography ( $SiO_2$ , EtOAc/Hept, 3/7) to afford the desired product as an white solid in 77% yield (13 mg, 23  $\mu$ mol).

$^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.12 (d,  $J = 8.7$  Hz, 2H), 7.80 – 7.76 (m, 1H), 7.70 (t,  $J = 7.7$  Hz, 2H), 7.61 (dd,  $J = 8.4, 1.0$  Hz, 2H), 7.45 (d,  $J = 8.7$  Hz, 2H), 7.15 (dd,  $J = 22.4, 8.1$  Hz, 4H), 6.74 (s, 1H), 2.38 (s, 3H).

$^{13}C$  NMR (100 MHz,  $CD_2Cl_2$ )  $\delta$  161.2, 145.9, 144.1 (q,  $J_{C-F} = 38.1$  Hz), 142.9, 142.3, 140.4, 134.1, 132.0, 131.1 (2C), 130.2 (2C), 129.3 (2C), 128.8 (2C), 126.7 (q,  $J_{C-F} = 227.6$  Hz), 126.3, 125.9 (2C), 125.2 (2C), 122.4, 106.5, 21.6.


**LCMS (ESI)  $m/z$  [M+H] $^+$**  561.2.

**IR ( $cm^{-1}$ ):** 2934, 1615, 1470, 1372, 1237, 1155, 1096, 976, 860, 764, 629.

**HRMS (ESI)  $m/z$  calcd for  $C_{25}H_{17}ClF_3N_5O_3S$  [M+H] $^+$ :** 560.0765; found: 560.0759.

**Pyrazole**

(4-chloro-3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)((4-(5-(*p*-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)sulfonyl)amide



$C_{28}H_{24}ClN_3O_3$

**MW:** 485  $g \cdot mol^{-1}$

**Yield:** 52%

Pink sticky solid

**IS9'** (14.3 mg, 25  $\mu$ mol, 1 equiv.) was dissolved in DCM (0.5 mL) and DBCO-COOH (9.2 mg, 28  $\mu$ mol, 1.1 equiv.) was added under stirring at room temperature. The reaction was left under stirring during 2 hours before being concentrated under reduced pressure. The reaction was quantitative according

to NMR analysis of the crude. The crude mixture was then purified by supercritical fluid chromatography to obtain a mixture of two regioisomers of the desired pyrazole product as a purple sticky solid in 52% yield (6.3 mg, 13  $\mu$ mol).

SFC Conditions: Column TORUS DEA 250x19 mm; 4.6  $\mu$ m.

Elution system:

Min	CO <sub>2</sub>	MeOH
0	95%	5%
1	95%	5%
10	50%	50%

Flow = 70 mL/min.

BPR = 120 bar.

*Since the purified product is a mixture of regioisomers, the following characterization report all the peaks for both isomers.*

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)**  $\delta$  7.67 (t,  $J$  = 8.3 Hz, 2H), 7.52 (dd,  $J$  = 24.0, 8.4 Hz, 3H), 7.42 (dd,  $J$  = 15.0, 6.9 Hz, 3H), 7.34 (dd,  $J$  = 22.1, 5.5 Hz, 1H), 7.26 (s, 1H), 7.20 (dd,  $J$  = 19.6, 5.3 Hz, 3H), 6.08 (dd,  $J$  = 75.0, 16.1 Hz, 1H), 4.42 (dd,  $J$  = 16.0, 6.1 Hz, 1H), 2.19 (s, 2H), 1.90 – 1.63 (m, 2H), 1.46 (s, 4H).

**<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)**  $\delta$  173.0, 172.5, 151.8, 140.8, 140.4, 138.1, 134.8, 134.7, 133.6, 132.5, 132.2, 131.8, 130.8, 130.4, 130.2, 129.9, 129.7, 129.6, 129.4, 129.1 (2C), 129.1, 128.9, 128.7, 128.6, 128.5, 128.0 (2C), 128.0 (2C), 127.3, 127.2, 125.2 (2C), 125.0 (2C), 124.2, 117.0, 52.5, 52.3, 33.6, 33.5, 30.9, 24.3.


**LCMS (ESI)  $m/z$  [M+H]<sup>+</sup>** 486.2.

**IR (cm<sup>-1</sup>)** : 3062, 2926, 2248, 1657, 1499, 1398, 1356, 908, 761, 727, 693.

**HRMS (ESI)  $m/z$  calcd for C<sub>28</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup>**: 486.1584; found: 486.1582.

### 3. Procedure and analytical data for bromination of iminosydnone


#### General procedure C: Bromination of iminosydnone substrates



To a solution of iminosydnone (1.0 equiv.) in DCM (0.5 M) was added NBS (2.0 – 6.0 equiv.). The mixture was stirred at 40 °C. The reaction was followed by LCMS. Once the reaction has reached completion (ca. 2 to 16 hours), the solvent was evaporated under reduced pressure to give the crude product. The crude product was then purified by chromatographic column to give the desired Br-iminosydnone product (heptane/ethyl acetate).

#### IS3''

*Benzoyl(4-bromo-3-(4-(ethoxycarbonyl)phenyl)-1,2,3-oxadiazol-3-ium-5-yl)amide*



$C_{18}H_{14}BrN_3O_4$   
**MW:** 415 g.mol<sup>-1</sup>  
**Yield:** 65%  
White solid

The product was obtained using general procedure C from iminosydnone IS3 (9 mg) and NBS (28 mg). The crude product was purified by chromatographic column (SiO<sub>2</sub>, EtOAc/Hept, 3/7) to afford the desired product as a white solid in 65% yield (7.2 mg, 17 μmols).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.33 (dd, *J* = 18.6, 8.0 Hz, 4H), 7.77 (d, *J* = 8.3 Hz, 2H), 7.47 (dt, *J* = 27.6, 7.5 Hz, 3H), 4.47 (q, *J* = 7.1 Hz, 2H), 1.44 (t, *J* = 7.1 Hz, 3H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 173.0, 165.7, 164.6, 136.8, 136.0, 135.1, 132.0, 131.6 (2C), 130.0 (2C), 128.2 (2C), 125.3 (2C), 92.6, 62.3, 14.4.


LCMS (ESI) *m/z* [M+H]<sup>+</sup> 416.

IR (cm<sup>-1</sup>): 2928, 1710, 1582, 1346, 1313, 1275, 1215, 1172, 1107, 1014, 866, 770, 715, 672.

HRMS (ESI) *m/z* calcd for C<sub>18</sub>H<sub>14</sub>BrN<sub>3</sub>O<sub>4</sub> [M+H]<sup>+</sup>: 416.0246; found: 416.0244.

#### IS15''

*(4-bromo-3-phenyl-1,2,3-oxadiazol-3-ium-5-yl)(tosyl)amide*



$C_{15}H_{12}BrN_3O_3S$   
**MW:** 393 g.mol<sup>-1</sup>  
**Yield:** 75%  
White solid

The product was obtained using general procedure **C** from iminosydnone **IS15** (50 mg) and NBS (113 mg). The crude product was purified by chromatographic column (SiO<sub>2</sub>, EtOAc/Hept, 3/7) to afford the desired product as a white solid in 75% yield (46.9 mg, 119 μmol).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.04 – 7.99 (m, 2H), 7.77 – 7.73 (m, 1H), 7.70 – 7.65 (m, 2H), 7.60 – 7.55 (m, 2H), 7.30 (d, *J* = 8.0 Hz, 2H), 2.42 (s, 3H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 162.5, 143.1, 139.3, 133.5, 132.6, 130.5 (2C), 129.4 (2C), 127.5 (2C), 125.0 (2C), 91.1, 21.7.


LCMS (ESI) *m/z* [M+H]<sup>+</sup> 394.

IR (cm<sup>-1</sup>) : 2926, 1602, 1464, 1361, 1285, 1146, 1088, 1005, 910, 854, 814, 764, 723, 686, 657, 603, 548.

HRMS (ESI) *m/z* calcd for C<sub>15</sub>H<sub>12</sub>BrN<sub>3</sub>O<sub>3</sub>S [M+H]<sup>+</sup>: 393.9861; found: 393.9858.

### IS8''

(4-bromo-3-(*p*-tolyl)-1,2,3-oxadiazol-3-ium-5-yl)(*tert*-butoxycarbonyl)amide



C<sub>14</sub>H<sub>16</sub>BrN<sub>3</sub>O<sub>3</sub>  
MW: 353 g.mol<sup>-1</sup>  
Yield: 90%  
White solid

The product was obtained using general procedure **C** from iminosydnone substrate **IS8** (50 mg) and NBS (64.7 mg). The crude product was purified by chromatographic column (SiO<sub>2</sub>, EtOAc/Hept, 3/7) to afford the desired product as a white solid in 90% yield (57.9 mg, 163 μmol).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.49 (d, *J* = 8.6 Hz, 2H), 7.44 (d, *J* = 8.4 Hz, 2H), 2.50 (s, 3H), 1.55 (s, 9H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 165.1, 158.6, 144.1, 130.8 (2C), 130.5, 124.8 (2C), 90.7, 79.9, 28.3 (3C), 21.7.

LCMS (ESI) *m/z* [M+H]<sup>+</sup> 356.


IR (cm<sup>-1</sup>) : 2976, 2931, 1614, 1454, 1366, 1288, 1208, 1148, 1052, 823, 735.

HRMS (ESI) *m/z* calcd for C<sub>14</sub>H<sub>16</sub>BrN<sub>3</sub>O<sub>3</sub> [M+H]<sup>+</sup>: 354.0453; found: 354.0450.



### III. Kinetic data for Iminosydnone/Cyclooctyne cycloaddition

Reactions were followed by measuring the decrease of the maximum absorbance signal of iminosydnone at different wavelengths after addition of DBCO-acid.



Reactions of iminosydnone pro-drug with DBCO were carried out in PBS/DMSO (8:2) mixtures at 37 °C, under stirring, at 150  $\mu\text{M}$  concentration of iminosydnone and 225  $\mu\text{M}$  concentration of DBCO using the following procedure.


To 1594  $\mu\text{L}$  of phosphate buffered saline (PBS, 10 mM) was added 372  $\mu\text{L}$  of DMSO and 10  $\mu\text{L}$  of the solution of iminosydnone (30 mM in DMSO). Absorbance spectrum of the solution was measured to identify the  $\lambda_{\text{max}}$  of the compound. Kinetic measurement was then started upon addition of 25  $\mu\text{L}$  of DBCO-COOH (18 mM in DMSO).

Second order reaction rate was determined by plotting  $\ln([A]/[B])/([A] - [B])$  versus time between 0% to 10% of conversion and analyzing by linear regression (**Equation S1**). Second order rate constant corresponds to the determined slope.


$$\frac{\ln\left(\frac{[A]}{[B]}\right)}{[A] - [B]} = kt + \text{const}$$

**Equation S1.** [A] – concentration of iminosydnone (M); [B] – concentration of DBCO (M); t – reaction time (sec); k – reaction rate ( $\text{M}^{-1}\cdot\text{sec}^{-1}$ ).


IS12':  $-\ln([SM]/([SM]+D))/D = f(t)$ , 150  $\mu\text{M}$ , 37  $^{\circ}\text{C}$






IS12': Abs = f(t), 150  $\mu\text{M}$ , 37  $^{\circ}\text{C}$






IS12': Conv% = f(t), 150  $\mu\text{M}$ , 37  $^{\circ}\text{C}$





Due to problem of solubility, reaction was carried out at 100  $\mu\text{M}$  of iminosydnone, 150 $\mu\text{M}$  of DBCO in PBS/DMSO (5:5) for compound **IS16'**.



Reactions of iminosydnonones with DBCO were either carried out in PBS/DMSO mixtures at physiological pH, under stirring, at 150  $\mu\text{M}$  concentration of iminosydnonones and 225  $\mu\text{M}$  concentration of DBCO or at 30  $\mu\text{M}$  concentration of iminosydnonones and 45  $\mu\text{M}$  concentration of DBCO using the following procedure.


When carried at 150  $\mu\text{M}$  of iminosydnonones :

- For 8/2 PBS/DMSO : To 1594  $\mu\text{L}$  of phosphate buffered saline (PBS, 10 mM) was added 372  $\mu\text{L}$  of DMSO and 10  $\mu\text{L}$  of the solution of iminosydnone (30 mM in DMSO) . Absorbance spectrum of the solution was measured to identify the  $\lambda_{\text{max}}$  of the compound. Kinetic measurement was then started upon addition of 25  $\mu\text{L}$  of DBCO-COOH (18 mM in DMSO).
- For 5/5 PBS/DMSO : To 1000 $\mu\text{L}$  of phosphate buffered saline (PBS, 10 mM) was added 965  $\mu\text{L}$  of DMSO and 10  $\mu\text{L}$  of the solution of iminosydnone (30 mM in DMSO) . Absorbance spectrum of the solution was measured to identify the  $\lambda_{\text{max}}$  of the compound. Kinetic measurement was then started upon addition of 25  $\mu\text{L}$  of DBCO-COOH (18 mM in DMSO).


When carried at 30  $\mu\text{M}$  of iminosydnonones :

To 797  $\mu\text{L}$  of phosphate buffered saline (PBS, 10 mM) was added 199  $\mu\text{L}$  of DMSO and 3  $\mu\text{L}$  of the solution of iminosydnone (10 mM in DMSO). Absorbance spectrum of the solution was measured to identify the  $\lambda_{\text{max}}$  of the compound. Kinetic measurement was then started upon addition of 1  $\mu\text{L}$  of DBCO-COOH (45 mM in DMSO).


**IS15'**:  $-\ln([SM]/([SM]+D))/D = f(t)$ , 150  $\mu$ M, 37  $^{\circ}$ C, 8/2  
PBS/DMSO




**IS7'**:  $-\ln([SM]/([SM]+D))/D = f(t)$ , 30  $\mu$ M, 37  $^{\circ}$ C, 8/2 PBS/DMSO




**IS6'**:  $-\ln([A]/([A]+D))/D = f(t)$ , 30  $\mu$ M, 37  $^{\circ}$ C, 8/2 PBS/DMSO




IS1':  $-\ln([SM]/([SM]+D))/D = f(t)$ , 30  $\mu$ M, 37  $^{\circ}$ C, 5/5 PBS/DMSO




IS3':  $-\ln([SM]/([SM]+D))/D = f(t)$ , 150  $\mu$ M, 37  $^{\circ}$ C, 8/2 PBS/DMSO




IS8':  $-\ln([SM]/([SM]+D))/D = f(t)$ , 150  $\mu$ M, 37  $^{\circ}$ C, 8/2 PBS/DMSO




**IS3''**:  $-\ln([SM]/([SM]+D))/D = f(t)$ , 150  $\mu$ M, 37  $^{\circ}$ C, 5/5  
PBS/DMSO



**IS8''**:  $-\ln([SM]/([SM]+D))/D = f(t)$ , 150  $\mu$ M, 37  $^{\circ}$ C, 8/2  
PBS/DMSO



Release of drugs upon SPICC reaction:



Reactions of **IS15'** with DBCO was carried out in PBS/DMSO (8:2) at 37  $^{\circ}$ C, under stirring, at 30  $\mu$ M concentration of iminosynone and 45  $\mu$ M concentration of DBCO using the following



procedure.

In a HPLC vial, the reagents were added in the order listed below (1 mL in total):


788  $\mu\text{L}$  of PBS (0.01 M), 10  $\mu\text{L}$  of **IS15'** solution (10 mM in DMSO), 1  $\mu\text{L}$  of 3-fluoro-4-nitrophenol as internal standard (at 100 mM in DMSO) and 200  $\mu\text{L}$  of DMSO.

The absorbance spectrum of the solution was first measured to get the T0. Then, 1  $\mu\text{L}$  of the DBCO solution (150 mM in DMSO) was added to the reaction. The reaction was monitored by HPLC after 1 hour of reaction.

Conditions of HPLC eluant:

T = 0 min: 95/05 ( $\text{H}_2\text{O}/\text{MeCN}$ )

T = 4 min: 100% MeCN





#### IV. Stability of chlorinated iminosydnone


Stability studies of chlorinated iminosydnone prodrugs were done in phosphate buffer saline solution pH 7.4 with 10% of DMSO at room temperature.

In a HPLC vial, 100  $\mu\text{L}$  of iminosydnone solution at 1 mM in DMSO were added to 899  $\mu\text{L}$  of PBS (0.1 M, pH 7.4). 1  $\mu\text{L}$  of 3-fluoro-4-nitrophenol (at 100 mM in DMSO) was then added as an internal standard.

The solution was stored at room temperature. Quantification of iminosydnone was carried out by HPLC analysis at different time and the percentage of the remaining compound was determined.




Stability **IS16'**, Pourcentage of IS = f(t), 100  $\mu$ M in PBS




# V. NMR Spectra


<sup>1</sup>H NMR (400 MHz, MeOD) (IS1)




<sup>13</sup>C NMR (100 MHz, MeOD) (IS1)




<sup>1</sup>H NMR (400 MHz, MeOD) (IS2)




<sup>13</sup>C NMR (100 MHz, MeOD) (IS2)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS3)




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS3)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS4)




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS4)



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS5)




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS5)







<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS8)




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS8)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS11)




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS11)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS12a)




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS12a)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS12)




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS12)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS13)




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS13)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS15)




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS15)




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ) (**IS1'**)




$^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ) (**IS1'**)



<sup>1</sup>H NMR (400 MHz, MeOD) (IS2')




<sup>13</sup>C NMR (100 MHz, MeOD) (IS2')







$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ) (**IS3'**)




$^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ) (**IS3'**)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (**IS4'**)



<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (**IS4'**)




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ) (IS5')




The product is not stable enough in solvent to afford a  $^{13}\text{C}$  NMR spectrum.


$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ) (IS6')



$^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ) (IS6')




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ) (**IS7'**)




The product is not stable enough in solvent to afford a  $^{13}\text{C}$  NMR spectrum.


$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ) (**IS8'**)




$^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ) (**IS8'**)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS9')




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS9')



<sup>1</sup>H NMR (400 MHz, CD<sub>2</sub>Cl<sub>2</sub>) (IS10')




<sup>13</sup>C NMR (100 MHz, CD<sub>2</sub>Cl<sub>2</sub>) (IS10')







$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ) (**IS11'**)



$^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ) (**IS11'**)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS13')




The product is not stable enough to afford a <sup>13</sup>C NMR.


<sup>1</sup>H NMR (400 MHz, MeOD) (**IS12'**)




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (**IS12'**)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS14')




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS14')




<sup>1</sup>H NMR (400 MHz, Acetone-d<sub>6</sub>) (IS15')




<sup>13</sup>C NMR (100 MHz, Acetone-d<sub>6</sub>) (IS15')




$^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ) (**IS16'**)




$^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ) (**IS16'**)




<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (Pyrazole)




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (Pyrazole)



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS3'')




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS3'')







<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS8'')




<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS8'')



<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) (IS15'')



<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) (IS15'')



## VI. DFT calculations


### Computational Details

Calculations were performed with the Gaussian 16 package. Geometry optimization of all the minima and transition structures was carried out at the M06-2X level of theory with the 6-31+G(d,p) basis set and the CPCM solvation model for water. The vibrational frequencies were computed at the same level to check whether each optimized structure is an energy minimum or a saddle-point and to obtain its zero-point, enthalpy, and free energy corrections. These corrections were obtained with a standard state of 298 K and 1 atm, using Grimme's quasiharmonic scheme for the treatment of small ( $<100\text{ cm}^{-1}$ ) frequencies,<sup>3</sup> using CYLview 2.0.<sup>4</sup>

Geometry optimization of the model iminosydnone mIS1-2 and DBCO:

For both model iminosydnones, two isomers displaying the amide carbonyl in a different orientation (forms 1 and 2) were considered and their geometries optimized at the M06-2X/6-31+G(d,p)/CPCM(H<sub>2</sub>O) level of theory. For **mIS1**, form 2 is 3.5 kcal/mol more stable than form 1, while for **mIS2**, form 1 is more stable by 1.3 kcal/mol.

Optimized geometry of the model iminosydnones:



<sup>3</sup> Grimme, S. *Chem. - Eur. J.* **2012**, *18*, 9955–9964.

<sup>4</sup> CYLview20; Legault, C. Y., Université de Sherbrooke, 2020 (<http://www.cylview.org>)

Cartesian Coordinates of mIS and DBCO:

**mIS1 form 1**

C -3.97486 1.29062 -0.35062  
C -4.73642 0.20418 0.08048  
C -4.11538 -0.98439 0.46599  
C -2.72818 -1.09572 0.42791  
C -1.99369 0.00228 -0.00780  
C -2.58650 1.19673 -0.40218  
N -0.55798 -0.10130 -0.05425  
N -0.02702 -1.20926 -0.46233  
O 1.30406 -1.00542 -0.37526  
C 1.58790 0.26121 0.08233  
C 0.33190 0.84560 0.29141  
N 2.77872 0.77077 0.27306  
H -4.45872 2.21137 -0.65665  
H -5.81758 0.28420 0.11661  
H -4.70864 -1.82575 0.80639  
H -2.22358 -2.00347 0.73876  
H -1.98268 2.02492 -0.75760  
H 0.05536 1.80922 0.68206  
C 5.18571 0.80678 0.30046  
H 5.22397 1.68817 -0.34569  
C 3.91296 0.03433 0.03386  
O 3.94659 -1.13418 -0.35733  
H 6.05445 0.17578 0.11579  
H 5.19561 1.16114 1.33462

**mIS1 form 2**

C 3.50731 -1.58471 -0.45293  
C 4.46418 -0.75651 0.13411  
C 4.10294 0.49490 0.63451  
C 2.78199 0.92735 0.55615  
C 1.84929 0.08261 -0.03685  
C 2.18217 -1.16746 -0.54711  
N 0.47967 0.51857 -0.12810  
N 0.23750 1.75653 -0.40138  
O -1.10270 1.85089 -0.39894  
C -1.69468 0.64280 -0.13149  
C -0.62421 -0.24302 0.04900  
N -3.00547 0.62028 -0.10410  
H 3.79014 -2.55428 -0.84725  
H 5.49480 -1.08779 0.20269  
H 4.84672 1.13474 1.09613  
H 2.47597 1.88803 0.95458  
H 1.43182 -1.79064 -1.02156  
H -0.59742 -1.28308 0.31390  
C -5.08869 -0.56846 0.17962  
H -5.43919 0.15729 0.91836  
C -3.57892 -0.59662 0.16715  
O -2.95370 -1.64053 0.38491  
H -5.48273 -1.55666 0.41416  
H -5.45906 -0.24351 -0.79661

**mIS2 form 1**

C 4.01841 0.64617 0.90338  
C 4.74072 -0.14528 0.00893  
C 4.08251 -1.02514 -0.85029  
C 2.69299 -1.11859 -0.82574  
C 2.00087 -0.31731 0.07460  
C 2.62925 0.56539 0.94593  
N 0.56203 -0.42296 0.11046  
N 0.03441 -1.58972 0.32117  
O -1.30140 -1.38191 0.27218  
C -1.60372 -0.06689 0.03715  
C -0.34596 0.55480 -0.06634  
N -2.78494 0.47345 -0.07193  
H 4.53431 1.32360 1.57449  
H 5.82292 -0.07598 -0.01737  
H 4.64705 -1.63712 -1.54474  
H 2.15521 -1.78665 -1.48937  
H 2.05105 1.16100 1.64422  
C -5.19442 0.51227 -0.11048  
H -5.23575 1.27953 0.66757  
C -3.92481 -0.29316 0.03709  
O -3.95243 -1.50739 0.23432  
H -6.06395 -0.13947 -0.03428  
H -5.19661 1.02674 -1.07509  
Cl 0.00358 2.16846 -0.42475

**mIS2 form 2**


C -3.67547 -1.22351 0.80911  
C -4.57763 -0.54732 -0.01397  
C -4.16036 0.54165 -0.77910  
C -2.83342 0.96258 -0.73143  
C -1.95859 0.26974 0.09688  
C -2.34597 -0.81653 0.87364  
N -0.58673 0.71345 0.16177  
N -0.35497 1.95254 0.44984  
O 0.98398 2.07115 0.40731  
C 1.60079 0.89079 0.08739  
C 0.53282 -0.01350 -0.06842  
N 2.89491 0.90077 -0.06425  
H -4.00554 -2.06530 1.40730  
H -5.61190 -0.87132 -0.05821  
H -4.86368 1.06292 -1.41871  
H -2.47958 1.79924 -1.32365  
H -1.63270 -1.31998 1.51761  
C 4.99794 -0.23795 -0.41086  
H 4.95489 -0.17242 -1.50195  
C 3.59518 -0.26362 0.14599  
O 3.16321 -1.23565 0.76728  
H 5.53589 -1.13888 -0.11817  
H 5.52544 0.64889 -0.05142  
Cl 0.51032 -1.58638 -0.69037

### DBCO model


C	-0.63546	-1.72895	-0.52545
C	0.57790	-1.77006	-0.48313
C	-1.91739	-1.17431	-0.21872
C	1.85665	-1.20533	-0.18549
C	-1.84725	-0.03507	0.62135
C	1.79296	0.14909	0.21949
C	-0.51743	0.44661	1.18826
N	0.53651	0.84257	0.22100
C	-3.03773	0.58954	0.98667
C	-4.26850	0.11146	0.53230
C	-4.32292	-1.00508	-0.30136
C	-3.14794	-1.65083	-0.67835
C	3.08595	-1.87210	-0.20580
C	2.95892	0.80525	0.60235
C	4.18136	0.13573	0.57155
C	4.24535	-1.19890	0.16606
C	0.38688	1.89361	-0.64945
C	-0.89874	2.68424	-0.57803
O	1.25799	2.17887	-1.46891
H	-0.70576	1.28233	1.86924
H	-0.08046	-0.35699	1.78651
H	-3.00576	1.46208	1.63436
H	-5.18325	0.61373	0.82943
H	-5.27929	-1.37413	-0.65670
H	-3.17584	-2.52289	-1.32302
H	3.12082	-2.91250	-0.51050
H	2.90221	1.84404	0.91134
H	5.08541	0.65759	0.86744
H	5.19865	-1.71630	0.14670
H	-1.18343	2.92693	0.44811
H	-0.75232	3.60308	-1.14370
H	-1.71623	2.11467	-1.02854

Transition structures (TS) and activation free energies ( $\Delta G^\ddagger_{\text{water}}$ ) for their reactions with DBCO


For each iminosydnone, we considered transition structures using both forms 1 and 2 with two conformations of the DBCO model. The resulting structures and activation free energies are shown below. The lowest-energy structures for **mIS1** use form 2, while for **mIS2** they use form 2, reproducing the above results.




**TS<sub>1a</sub>**:  $\Delta G^\ddagger_{\text{water}} = 25.4 \text{ kcalmol}^{-1}$




**TS<sub>1b</sub>**:  $\Delta G^\ddagger_{\text{water}} = 25.5 \text{ kcalmol}^{-1}$




**TS<sub>1c</sub>**:  $\Delta G^\ddagger_{\text{water}} = 23.0 \text{ kcalmol}^{-1}$




**TS<sub>1d</sub>**:  $\Delta G^\ddagger_{\text{water}} = 23.0 \text{ kcalmol}^{-1}$




**TS<sub>2a</sub>**:  $\Delta G^\ddagger_{\text{water}} = 21.2 \text{ kcalmol}^{-1}$



**TS<sub>2b</sub>**:  $\Delta G^\ddagger_{\text{water}} = 20.5 \text{ kcalmol}^{-1}$



**TS<sub>2c</sub>**:  $\Delta G^\ddagger_{\text{water}} = 24.2 \text{ kcalmol}^{-1}$



**TS<sub>2d</sub>**:  $\Delta G^\ddagger_{\text{water}} = 23.4 \text{ kcalmol}^{-1}$

Cartesian coordinates for all TS:

**TS<sub>1a</sub>** (mIS1 form 1 conf1)

N -0.62967 -2.03469 -0.99045  
N -0.61486 -2.24026 0.32970  
O -1.94336 -2.07113 0.70769  
C -2.58752 -1.34356 -0.24212  
C -1.62108 -1.17594 -1.29496  
N -3.80469 -0.90951 -0.21969  
C 0.61566 -2.17534 -1.67328  
C 1.05473 -1.16145 -2.52204  
C 2.27525 -1.32046 -3.17518  
C 3.04388 -2.46400 -2.96141  
C 2.59260 -3.46122 -2.09467  
C 1.36866 -3.32582 -1.44669  
C -4.59401 -1.06661 0.91656  
C -0.67512 0.40947 0.00749  
C -0.00890 -0.31897 0.78602  
C -1.01989 1.74497 -0.43246  
C 1.08147 -0.45029 1.71970  
C -0.30540 2.83762 0.11302  
C 2.02625 0.59491 1.74827  
C 0.73751 2.64495 1.19421  
N 1.84744 1.72108 0.88760  
C -0.62095 4.12992 -0.30274  
C -1.63097 4.36456 -1.23524  
C -2.34295 3.29043 -1.76390  
C -2.03797 1.99254 -1.36402  
C 1.24560 -1.54026 2.58651  
C 3.10992 0.54036 2.61969  
C 3.26415 -0.54994 3.47277  
C 2.32784 -1.58601 3.45867  
C 2.74659 1.91930 -0.12724  
C 2.57747 3.15650 -0.97730  
O 3.64872 1.11335 -0.35010  
H -1.82622 -0.86109 -2.30713  
H 0.46804 -0.25830 -2.65810  
H 2.62949 -0.53975 -3.83964  
H 3.99592 -2.57842 -3.46877  
H 3.18920 -4.35171 -1.92916  
H 0.99267 -4.09555 -0.78149  
H 1.14420 3.62068 1.48000  
H 0.24958 2.23462 2.08252  
H -0.06706 4.96832 0.11200  
H -1.86016 5.37979 -1.54189  
H -3.13700 3.45890 -2.48377  
H -2.61564 1.16412 -1.75830  
H 0.52205 -2.34703 2.56304  
H 3.82748 1.35472 2.61849  
H 4.11093 -0.58872 4.15003  
H 2.44412 -2.43304 4.12663  
H 2.37958 4.04946 -0.38025  
H 3.49307 3.29333 -1.55067  
H 1.73971 3.02240 -1.66799  
O -4.24988 -1.64073 1.94205  
C -5.96152 -0.44927 0.76511  
H -6.47690 -0.90406 -0.08527  
H -6.54281 -0.59307 1.67484  
H -5.85937 0.61787 0.54920

**TS<sub>1b</sub>** (mIS1 form 1 conf2)

N 2.11742 1.43914 -0.10540  
N 1.78966 0.89865 -1.28160  
O 0.90132 1.81563 -1.83423  
C 0.38646 2.58984 -0.84417  
C 1.08983 2.18334 0.34425  
N -0.53076 3.49471 -0.94090  
C 3.05958 0.71494 0.68415  
C 2.77272 0.43512 2.01853  
C 3.70577 -0.28225 2.76465  
C 4.88941 -0.72406 2.17444  
C 5.15043 -0.44609 0.83146  
C 4.23644 0.28208 0.07596  
C -1.17485 3.72877 -2.15300  
C -0.25171 0.38044 0.36838  
C 0.31077 -0.34250 -0.49158  
C -1.22240 0.50634 1.43377  
C 0.41274 -1.62133 -1.15318  
C -1.76556 -0.68101 1.97510  
C -0.59789 -2.56907 -0.88896  
C -1.37481 -2.03359 1.42012  
N -1.67760 -2.23506 -0.01410  
C -2.64631 -0.59408 3.05211  
C -3.02342 0.64125 3.57712  
C -2.52157 1.81346 3.01354  
C -1.62246 1.74573 1.95340  
C 1.47357 -1.98069 -1.99852  
C -0.53930 -3.83635 -1.46261  
C 0.51311 -4.17507 -2.30911  
C 1.52019 -3.24578 -2.57398  
C -2.94932 -2.22192 -0.53004  
C -4.09709 -2.00704 0.42806  
O -3.15244 -2.36855 -1.73395  
H 1.11859 2.71530 1.28362  
H 1.83586 0.75428 2.46420  
H 3.49756 -0.50487 3.80550  
H 5.60884 -1.28624 2.76028  
H 6.07149 -0.78804 0.37210  
H 4.42688 0.52185 -0.96468  
H -0.29405 -2.16820 1.51829  
H -1.85047 -2.82414 2.00943  
H -3.05199 -1.50764 3.47969  
H -3.71261 0.68653 4.41390  
H -2.82336 2.78057 3.40205  
H -1.23828 2.65962 1.51111  
H 2.25505 -1.25739 -2.19656  
H -1.32936 -4.54770 -1.24448  
H 0.54919 -5.16346 -2.75527  
H 2.34568 -3.50805 -3.22739  
H -3.99068 -2.58891 1.34591  
H -4.16294 -0.95102 0.70411  
H -5.01252 -2.29692 -0.08571  
O -0.87528 3.21271 -3.22224  
C -2.30132 4.72359 -2.03058  
H -2.78631 4.86469 -2.99552  
H -3.02615 4.36817 -1.29297  
H -1.90851 5.67678 -1.66597



**TS<sub>1c</sub> (mIS1 form 2 conf1)**

N 0.67724 2.20487 -0.31423  
 N 0.25809 2.21023 0.95558  
 O 1.42767 2.07338 1.68558  
 C 2.39255 1.53274 0.90021  
 C 1.79547 1.45253 -0.41056  
 N 3.53123 1.25549 1.44792  
 C -0.32873 2.35474 -1.31559  
 C -0.39682 1.44132 -2.36551  
 C -1.39475 1.60017 -3.32493  
 C -2.31452 2.64253 -3.21729  
 C -2.23764 3.53876 -2.14946  
 C -1.23753 3.40399 -1.19120  
 C 4.57392 0.87036 0.61339  
 C 0.61064 -0.34555 0.36111  
 C -0.28559 0.26614 1.00095  
 C 1.12350 -1.60830 -0.13058  
 C -1.58748 0.24003 1.62550  
 C 0.37234 -2.78383 0.11020  
 C -2.43625 -0.83518 1.29884  
 C -0.91689 -2.75631 0.90246  
 N -1.96679 -1.84535 0.40536  
 C 0.85723 -4.00682 -0.34946  
 C 2.06506 -4.09454 -1.04086  
 C 2.80172 -2.93814 -1.28373  
 C 2.33293 -1.70702 -0.83271  
 C -2.03939 1.21033 2.53170  
 C -3.70759 -0.92571 1.85738  
 C -4.14703 0.04809 2.75118  
 C -3.30825 1.11105 3.09212  
 C -2.54151 -1.94002 -0.83454  
 C -2.08377 -3.06291 -1.73514  
 O -3.39068 -1.13230 -1.20853  
 H 2.31653 1.29586 -1.34085  
 H 0.30095 0.61221 -2.42603  
 H -1.45927 0.89655 -4.14788  
 H -3.09292 2.75659 -3.96424  
 H -2.95169 4.35080 -2.06589  
 H -1.15205 4.09770 -0.36178  
 H -1.31853 -3.77250 0.97446  
 H -0.70070 -2.42890 1.92298  
 H 0.27642 -4.90716 -0.16527  
 H 2.42295 -5.05852 -1.38732  
 H 3.74275 -2.98927 -1.82166  
 H 2.92391 -0.81567 -1.01137  
 H -1.39115 2.04057 2.78643  
 H -4.34429 -1.76071 1.58252  
 H -5.13917 -0.02539 3.18409  
 H -3.64559 1.86662 3.79389  
 H -1.98003 -4.01090 -1.20307  
 H -2.81700 -3.16712 -2.53361  
 H -1.11231 -2.81535 -2.17330  
 O 4.48670 0.74493 -0.60572  
 C 5.86029 0.61153 1.35068  
 H 6.64636 0.32915 0.65192  
 H 6.15183 1.50714 1.90573  
 H 5.70370 -0.18640 2.08203

**TS<sub>1d</sub> (mIS1 form 2 conf2)**

N -2.43597 -0.09584 -0.57592  
 N -1.74131 0.58079 -1.49474  
 O -1.28216 -0.40741 -2.35038  
 C -1.29713 -1.60391 -1.71172  
 C -1.90124 -1.32765 -0.42961  
 N -0.83019 -2.62939 -2.34645  
 C -3.07594 0.68097 0.43419  
 C -2.89553 0.35515 1.77665  
 C -3.52719 1.13566 2.74298  
 C -4.30499 2.22989 2.36602  
 C -4.46078 2.54846 1.01568  
 C -3.84994 1.77025 0.03729  
 C -1.00894 -3.88368 -1.77486  
 C 0.08609 -0.37557 0.17011  
 C -0.02040 0.72796 -0.42806  
 C 0.81950 -1.19717 1.11178  
 C 0.54410 2.02175 -0.74110  
 C 1.89823 -0.60981 1.81482  
 C 1.89981 2.23520 -0.42021  
 C 2.28649 0.83508 1.59388  
 N 2.64787 1.19301 0.20677  
 C 2.58608 -1.36589 2.76222  
 C 2.24558 -2.69419 3.01414  
 C 1.20074 -3.28082 2.30409  
 C 0.49074 -2.53601 1.36612  
 C -0.18756 3.07386 -1.31353  
 C 2.50181 3.46305 -0.68087  
 C 1.76695 4.49330 -1.26172  
 C 0.42007 4.29789 -1.57121  
 C 3.71523 0.65628 -0.46634  
 C 4.56966 -0.35363 0.26274  
 O 3.96290 0.97399 -1.62831  
 H -2.29041 -2.05731 0.26188  
 H -2.26410 -0.47911 2.06500  
 H -3.39848 0.89214 3.79198  
 H -4.78985 2.83566 3.12415  
 H -5.06727 3.39811 0.72147  
 H -3.97252 1.99010 -1.01795  
 H 1.44289 1.47897 1.85686  
 H 3.10913 1.09883 2.26651  
 H 3.40776 -0.90812 3.30742  
 H 2.79615 -3.26436 3.75515  
 H 0.92980 -4.31641 2.48233  
 H -0.32512 -3.00144 0.82397  
 H -1.23195 2.91937 -1.55498  
 H 3.54828 3.59853 -0.42702  
 H 2.24239 5.44731 -1.46424  
 H -0.15908 5.10144 -2.01397  
 H 4.79455 -0.04892 1.28704  
 H 4.05659 -1.31853 0.30389  
 H 5.49631 -0.46801 -0.29779  
 O -1.53814 -4.08824 -0.68515  
 C -0.48461 -5.00591 -2.62959  
 H -0.65329 -5.96432 -2.14087  
 H -0.98043 -4.98654 -3.60384  
 H 0.58417 -4.85716 -2.80711

**TS<sub>2a</sub>** (MIS2 form 1 conf1)

N 0.58348 2.01306 -0.51792  
 N 0.50156 2.03862 0.81932  
 O 1.81318 1.82633 1.24203  
 C 2.51593 1.23132 0.24817  
 C 1.59878 1.19482 -0.87003  
 N 3.74863 0.86642 0.25513  
 C -0.63383 2.26389 -1.22880  
 C -1.21639 1.25576 -1.99345  
 C -2.41721 1.52897 -2.64436  
 C -3.01874 2.78031 -2.51437  
 C -2.42484 3.77136 -1.73044  
 C -1.22079 3.51825 -1.08055  
 C 4.45178 0.77906 1.45836  
 C 0.58912 -0.54809 0.29150  
 C -0.15875 0.14277 1.02934  
 C 0.96434 -1.85722 -0.19622  
 C -1.38805 0.24154 1.77855  
 C 0.10206 -2.94517 0.07549  
 C -2.37910 -0.72501 1.51128  
 C -1.11790 -2.78956 0.95927  
 N -2.10596 -1.76447 0.57026  
 C 0.44103 -4.21210 -0.39598  
 C 1.61989 -4.42654 -1.10969  
 C 2.48424 -3.36065 -1.34992  
 C 2.15755 -2.08591 -0.89603  
 C -1.64583 1.23958 2.72909  
 C -3.60003 -0.67917 2.17901  
 C -3.84578 0.32024 3.11733  
 C -2.86501 1.27464 3.39613  
 C -2.86102 -1.84016 -0.57342  
 C -2.58024 -2.98985 -1.51228  
 O -3.71306 -0.99559 -0.83793  
 H -0.75387 0.27618 -2.06484  
 H -2.88907 0.75323 -3.23679  
 H -3.95574 2.98355 -3.02216  
 H -2.89487 4.74342 -1.62927  
 H -0.73367 4.27321 -0.47277  
 H -1.61805 -3.75889 1.05380  
 H -0.78321 -2.51127 1.96237  
 H -0.22475 -5.04732 -0.19328  
 H 1.86399 -5.42230 -1.46499  
 H 3.41361 -3.51832 -1.88718  
 H 2.84493 -1.26376 -1.06151  
 H -0.88546 1.98504 2.93161  
 H -4.35126 -1.42899 1.95294  
 H -4.79942 0.35105 3.63388  
 H -3.05320 2.04970 4.13160  
 H -2.53559 -3.94967 -0.99228  
 H -3.37440 -3.01374 -2.25673  
 H -1.62034 -2.83706 -2.01445  
 O 3.92895 0.72816 2.56216  
 C 5.94291 0.70122 1.26351  
 H 6.28777 1.57905 0.71036  
 H 6.44593 0.64224 2.22756  
 H 6.18390 -0.17813 0.65985  
 Cl 2.06716 0.94356 -2.48438

**TS<sub>2b</sub>** (MIS2 form 1 conf2)

N 1.70001 1.64173 0.23006  
 N 1.06349 1.46140 1.39356  
 O 1.76084 0.42318 2.00709  
 C 2.44776 -0.27296 1.07119  
 C 2.23258 0.46215 -0.15604  
 N 3.19040 -1.31202 1.22994  
 C 1.19976 2.69917 -0.59407  
 C 0.64574 2.41312 -1.84041  
 C 0.13171 3.46620 -2.59395  
 C 0.16307 4.76893 -2.09624  
 C 0.71117 5.03074 -0.83949  
 C 1.23805 3.99206 -0.07770  
 C 3.18433 -2.00683 2.44145  
 C 0.12111 -0.49619 -0.12819  
 C -0.45106 0.31118 0.64504  
 C 0.03719 -1.52188 -1.14116  
 C -1.69287 0.83747 1.16595  
 C -1.18068 -1.64609 -1.84743  
 C -2.88270 0.19146 0.76952  
 C -2.37491 -0.79617 -1.47034  
 N -2.82786 -0.96391 -0.07084  
 C -1.26699 -2.56684 -2.89007  
 C -0.18862 -3.38950 -3.21383  
 C 0.99249 -3.30539 -2.47727  
 C 1.10778 -2.37273 -1.45090  
 C -1.78014 1.97327 1.98517  
 C -4.11807 0.67994 1.18613  
 C -4.18946 1.80132 2.00837  
 C -3.01812 2.44643 2.40671  
 C -3.28410 -2.15286 0.44271  
 C -3.36519 -3.34213 -0.48494  
 O -3.60887 -2.25503 1.62426  
 H 0.60587 1.39363 -2.21007  
 H -0.30137 3.26334 -3.56731  
 H -0.24150 5.58256 -2.68892  
 H 0.73538 6.04395 -0.45374  
 H 1.67704 4.16989 0.89825  
 H -2.12466 0.26310 -1.57793  
 H -3.20591 -1.00003 -2.15325  
 H -2.19841 -2.65581 -3.44358  
 H -0.27751 -4.10311 -4.02635  
 H 1.82726 -3.95985 -2.70585  
 H 2.02826 -2.29980 -0.87975  
 H -0.87068 2.47867 2.28463  
 H -5.01874 0.16520 0.86715  
 H -5.15636 2.17208 2.33216  
 H -3.06822 3.32392 3.04279  
 H -3.75729 -3.08229 -1.47014  
 H -2.37182 -3.77865 -0.62096  
 H -4.01396 -4.07966 -0.01449  
 O 2.38564 -1.81877 3.34779  
 C 4.26111 -3.05726 2.51625  
 H 4.22356 -3.56795 3.47731  
 H 4.12358 -3.77580 1.70340  
 H 5.23982 -2.59091 2.37453  
 Cl 3.16923 0.26897 -1.55875

**TS<sub>2c</sub>** (mIS2 form 2 conf1)

N 0.52924 2.12907 0.13079  
 N 0.10665 1.89383 1.37825  
 O 1.27259 1.60617 2.07326  
 C 2.24207 1.19531 1.21054  
 C 1.64050 1.39321 -0.10166  
 N 3.32974 0.71837 1.68298  
 C -0.48031 2.52576 -0.80641  
 C -0.85368 1.67134 -1.84180  
 C -1.86665 2.08193 -2.70537  
 C -2.49398 3.31398 -2.51964  
 C -2.11391 4.14787 -1.46695  
 C -1.09755 3.75677 -0.60018  
 C 4.51433 0.68467 0.95675  
 C 0.42791 -0.54362 0.44779  
 C -0.50421 0.01604 1.08235  
 C 0.98968 -1.76978 -0.07808  
 C -1.86902 -0.03712 1.55471  
 C 0.20288 -2.94508 -0.03432  
 C -2.69485 -1.04403 1.01486  
 C -1.16918 -2.95528 0.60387  
 N -2.14373 -1.97663 0.08456  
 C 0.73469 -4.13899 -0.51817  
 C 2.02962 -4.20018 -1.03161  
 C 2.81098 -3.04775 -1.06413  
 C 2.29161 -1.84614 -0.59222  
 C -2.40697 0.84727 2.50119  
 C -4.02593 -1.14843 1.40862  
 C -4.54976 -0.25866 2.34311  
 C -3.73624 0.73370 2.89327  
 C -2.61780 -1.98732 -1.20250  
 C -2.07188 -3.04205 -2.13603  
 O -3.44020 -1.15972 -1.58939  
 H -0.37711 0.70379 -1.96193  
 H -2.17196 1.42998 -3.51642  
 H -3.28360 3.62425 -3.19588  
 H -2.60318 5.10487 -1.32283  
 H -0.77731 4.38878 0.22128  
 H -1.59164 -3.96321 0.53728  
 H -1.06115 -2.72979 1.66832  
 H 0.12522 -5.03864 -0.48808  
 H 2.42339 -5.14192 -1.39935  
 H 3.82333 -3.07963 -1.45358  
 H 2.91068 -0.95810 -0.61760  
 H -1.77692 1.62325 2.91886  
 H -4.64222 -1.92908 0.97433  
 H -5.58811 -0.34405 2.64588  
 H -4.13954 1.42288 3.62774  
 H -2.04708 -4.03296 -1.67715  
 H -2.70648 -3.06324 -3.02059  
 H -1.05109 -2.78508 -2.43382  
 O 4.88064 1.59682 0.22987  
 C 5.36270 -0.52875 1.23305  
 H 6.24649 -0.52104 0.59670  
 H 5.66229 -0.52024 2.28500  
 H 4.78184 -1.44074 1.06873  
 Cl 2.42449 1.42961 -1.61230

**TS<sub>2d</sub>** (mIS2 form 2 conf2)

N -1.33056 1.86560 -0.42492  
 N -0.52979 1.71572 -1.48588  
 O -1.23205 0.85651 -2.31531  
 C -2.15454 0.16145 -1.59889  
 C -2.06163 0.73767 -0.26582  
 N -2.79668 -0.78777 -2.16758  
 C -0.85365 2.76403 0.58386  
 C -0.49457 2.28548 1.84258  
 C 0.01066 3.18885 2.77499  
 C 0.16340 4.53461 2.44069  
 C -0.18953 4.98990 1.16952  
 C -0.70474 4.10251 0.22919  
 C -4.04195 -1.21879 -1.72772  
 C -0.07111 -0.48081 -0.09648  
 C 0.69747 0.32524 -0.67817  
 C -0.24551 -1.61493 0.78082  
 C 2.05512 0.72988 -0.97249  
 C 0.84774 -1.99681 1.59156  
 C 3.09096 -0.12847 -0.54886  
 C 2.18152 -1.29439 1.46257  
 N 2.77853 -1.35768 0.10995  
 C 0.68294 -3.03389 2.50802  
 C -0.52472 -3.72379 2.60660  
 C -1.58496 -3.38438 1.76732  
 C -1.44614 -2.33289 0.86751  
 C 2.39353 1.93959 -1.59809  
 C 4.42238 0.22243 -0.75486  
 C 4.74322 1.41956 -1.38925  
 C 3.72603 2.27760 -1.80849  
 C 3.13711 -2.52941 -0.50916  
 C 2.93675 -3.82124 0.24729  
 O 3.59726 -2.53347 -1.64934  
 H -0.59585 1.23340 2.08714  
 H 0.29287 2.83522 3.76064  
 H 0.55997 5.23030 3.17260  
 H -0.07014 6.03614 0.91046  
 H -0.99324 4.43178 -0.76340  
 H 2.06343 -0.23075 1.68774  
 H 2.88624 -1.70066 2.19526  
 H 1.51944 -3.31909 3.14111  
 H -0.63041 -4.53103 3.32377  
 H -2.52162 -3.92982 1.81755  
 H -2.27544 -2.06254 0.22393  
 H 1.60394 2.60889 -1.91519  
 H 5.20025 -0.45598 -0.41944  
 H 5.78340 1.68339 -1.54922  
 H 3.97029 3.21540 -2.29631  
 H 3.22461 -3.74385 1.29742  
 H 1.88509 -4.11854 0.20634  
 H 3.53904 -4.58455 -0.24335  
 O -4.90095 -0.46156 -1.29849  
 C -4.28636 -2.69020 -1.93899  
 H -3.47060 -3.28044 -1.51301  
 H -5.23796 -2.97943 -1.49550  
 H -4.30396 -2.89259 -3.01402  
 Cl -3.15120 0.53171 1.02106

Quasiharmonic-corrected free energies of all structures:

Molecule	G (with Grimme correction) in Hartrees
<b>mIS1 form 1</b>	-700.707867
<b>mIS1 form 2</b>	-700.713499
<b>mIS2 form 1</b>	-1160.273641
<b>mIS2 form 2</b>	-1160.271606
<b>DBCO model</b>	-785.066646
<b>TS 1a</b>	-1485.739604
<b>TS 1b</b>	-1485.739511
<b>TS 1c</b>	-1485.743541
<b>TS 1d</b>	-1485.743529
<b>TS 2a</b>	-1945.306544
<b>TS 2b</b>	-1945.307679
<b>TS 2c</b>	-1945.301638
<b>TS 2d</b>	-1945.302968